Methods and Compositions for Treating Neurological Disorders

Abstract

The present disclosure relates to methods and compositions for treating neurological disorders, such as neurodegenerative diseases, neurological disorders, cerebral ischemia, and neurotrauma.

Description

[Background technology]

[0001] The present disclosure relates to the field of neurological disorders. In particular, the present disclosure relates to methods and compositions for treating neurological disorders, such as neurodegenerative diseases, neurological disorders, cerebral ischemia, and neurotrauma.

[0002] Neurological diseases are generally recognized as diseases and conditions that cause or are associated with damage to nerve cells / tissues. Such damage may be the result of, for example, degeneration of nerve tissue, physical trauma to nerve tissue, and / or inflammation / oxidative stress within nerve tissue. Clinical management of neurological diseases is hampered by the progressive nature of neurological diseases, as well as the limited efficacy and severe side effects of drugs currently available for treating these diseases. As such, conditions associated with degeneration and / or damage / trauma to the nervous system have eluded most traditional pharmacological attempts to alleviate or cure these conditions.

[0003] Healthy proteostasis (protein synthesis and degradation) is the driving force behind the health and longevity of organisms, and impaired proteostasis has been discovered as an underlying mechanism of neurological disease and aging that influences the development of age-related pathologies such as Alzheimer's disease (AD). Protein aggregates are involved in proteostasis-based cytocompatibility competition, an evolutionarily conserved process for maintaining homeostasis and function of adult tissues. This process relies on the clearance of damaged, stressed, and / or senescent cells by healthy cells, preventing the accumulation of cells that lead to cell and tissue failure and the development of chronic neurological diseases.

[0004] Proteins that form protein aggregates can spread to distant organs via the circulation, which explains why several comorbidities such as AD and type 2 diabetes are strongly associated. Community-based control studies and pathological analyses of autopsies from brain and pancreas within the same community have shown that T2D and prediabetes are more prevalent in AD than in non-AD control subjects. In T2D cases presenting with amyloid plaques, the duration of T2D correlated with the density of diffuse and senile plaques associated with AD.

[0005] There is a need for new modalities for treating neurological diseases and neurotrauma, such as neurodegenerative diseases, neurological disorders, cerebral ischemia, etc. The methods and compositions provided herein address these needs. Summary of the Invention

[0006] The present disclosure provides methods and compositions for treating neurological diseases, such as neurodegenerative diseases, neurological disorders, cerebral ischemia, and neurotrauma. More specifically, the present disclosure provides a method for treating a neurological disease, comprising administering an effective amount of a HIF1-α pathway inhibitor or a HIF1-α inhibitor and an effective amount of a PFKFB3 inhibitor to a subject suffering from or at risk of suffering from a neurological disease, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0007] Furthermore, many neurological diseases such as AD show comparable histopathology to T2D, with amyloid protein aggregates originating from amyloid beta protein (Aβ) in the brain in AD and human islet amyloid pancreatic polypeptide (hIAPP) in the pancreas in T2D. Furthermore, hIAPP and Aβ exert their toxicity through similar mechanisms, including loss of calcium homeostasis, chronic injury, and neuroinflammation. Aβ and hIAPP protein aggregates share the induction of the same pathological cascades, including the hypoxia-inducible factor alpha (HIF1α) and PFKFB3 pathways. A key mechanism by which Aβ and hIAPP lead to the pathology seen in AD and T2D involves dysregulation of calcium homeostasis (neurons and astrocytes, as well as beta cells in T2D), resulting in neuronal and beta cell damage and loss. Aβ and hIAPP also cause activation of microglia, triggering neuroinflammatory responses that further exacerbate AD and T2D.

[0008] Interestingly, in AD, not all neurons damaged by Aβ protein aggregates in affected regions die. There appears to be a population of neurons that, by acquiring tolerance to Aβ, survive in the same conditions that cause surrounding cells to die. Surviving neurons that are resistant to Aβ aggregates are dysfunctional and are characterized by high expression levels of HIF1α and PFKFB3. Aβ-resistant neurons increase aerobic glycolysis, contributing to cognitive impairment and dementia in AD. Not only are Aβ-resistant neurons glycolytic by adopting glycolytic metabolism via HIF1α-PFKFB3 activation, but aerobic glycolysis is also increased in the frontal and temporal cortex of AD patients, and Aβ-resistant neurons contribute to the impairment of AD-affected brain regions. Thus, elevated HIF1α and PFKFB3 promote the survival of Aβ-stressed neurons at the expense of neuronal function and are associated with functional and cognitive impairment, memory loss, and dementia associated with neurological diseases such as AD.

[0009] The inventors have surprisingly found that a combination of HIF1α inhibitors and PFKFB3 inhibitors can alleviate and possibly even reverse the damage caused by neurological diseases such as AD. Without being bound by theory, in the context of AD, the disclosed method results in the regeneration of neurons after eliminating Aβ stress and dysfunctional neurons through cell competitive activation, thereby preventing or reducing motor decline, functional and memory impairment, and brain degeneration, and possibly even leading to increased regeneration of neurons and improved recovery of cognitive and memory function.

[0010] The methods and compositions provided herein are useful for treating chronic and acute neurological diseases. In some embodiments, the present disclosure provides methods and compositions for treating neurodegenerative diseases, such as neurological diseases selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), dementia, mild cognitive impairment (MCI), age-associated memory impairment (AAMI), and neuropathy.

[0011] In some embodiments, the present disclosure provides methods and compositions for treating acute neurological disorders. In further embodiments, the present disclosure provides methods and compositions for treating a neurological disorder selected from stroke, neurotrauma (e.g., traumatic brain injury or spinal cord injury), tethered spinal cord syndrome, cerebral ischemia, and global hypoxia-ischemia.

[0012] In some embodiments, the present disclosure provides: [1] A method of treating a neurological disorder in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α. [2] The method according to [1], wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. [3] The method of [1], wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor. [4] The method of [1], wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor. [5] The method according to any one of [1] to [4], wherein the method according to any one of 1(a) to 1(c) is administered as a prophylactic treatment for a neurological disease. [6] The method according to any one of [1] to [4], wherein the subject is suffering from or at risk of suffering from a neurological disease. [7] The method according to any one of [1] to [4], wherein the subject is suffering from or has been diagnosed with a neurological disease. [8] The method according to any one of [1] to [7], wherein the neurological disease is a neurodegenerative disease, dementia, neurological disorder, or neurotrauma. [9] The method according to any one of [1] to [8], wherein the neurological disease is a neurodegenerative disease.

[10] The method according to any one of [1] to [8], wherein the neurological disease is dementia.

[11] The method according to any one of [1] to [8], wherein the neurological disease is a neuropathy.

[12] The method according to any one of [1] to [8], wherein the neurological disease is a neurotrauma such as a spinal cord injury or a traumatic brain injury.

[13] The method of any one of [1] to

[12] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[14] The method according to any one of [1] to

[13] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[15] The method according to any one of [1] to

[14] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[16] The method according to any one of [1] to

[15] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[17] The method of

[16] , wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[18] The method according to

[16] or

[17] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[19] The method of any one of [1] to

[18] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[20] The method according to any one of [1] to

[19] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[21] The method according to any one of [1] to

[20] , wherein the administered PFKFB3 inhibitor is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) Formula 1 to Formula 53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A to Figure 1C or Figure 1D; (c) Formula AZ44 to Formula AZ70 or Formula AZ71, or a salt thereof, as shown in Figure 1E; or (d) AZ67 or a salt thereof.

[22] The method according to any one of [1] to

[21] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[23] The method according to any one of [1] to

[22] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[24] The method according to any one of [1] to

[23] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of a neurological disease.

[25] The method according to any one of [1] to

[24] , wherein treating a neurological disease includes delaying the onset of a neurological disease.

[26] The method according to any one of [1] to

[23] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of a neurological disease.

[27] The method of

[26] , wherein the method results in alleviation of one or more symptoms of a neurological disease in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[28] The method of

[27] , wherein one or more alleviated symptoms of the neurological disease are indicated by reduced apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissue; increased survival and / or function of neuronal cells and / or tissue (e.g., neurons); reduced or delayed neurodegeneration; restoration of motor function; reduced long-term damage to neuronal cells / tissue and / or surrounding cells / tissues; reduced inflammation of neuronal cells / tissue; reduced oxidative stress to neuronal cells / tissue; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and prolonged survival / survival.

[29] The method of

[27] or

[28] , wherein one or more symptoms of the neurological disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[30] The method of any one of

[27] to

[29] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[31] The method of any one of

[27] to

[30] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[32] The method according to any one of [1] to

[31] , further comprising administering an additional therapeutic agent to the subject.

[33] A method of treating a neurodegenerative disease in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[34] The method of

[33] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor.

[35] The method of

[33] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor.

[36] The method of

[33] , wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor.

[37] The method according to any one of

[33] to

[36] , wherein the method according to any one of 1(a) to 1(c) is administered as a prophylactic treatment for a neurodegenerative disease.

[38] The method according to any one of

[33] to

[36] , wherein the subject is suffering from or at risk of suffering from a neurodegenerative disease.

[39] The method of any one of

[33] to

[36] , wherein the subject is suffering from or has been diagnosed as suffering from a neurodegenerative disease.

[40] The method according to any one of

[33] to

[39] , wherein the neurodegenerative disease is selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, frontotemporal lobar degeneration, or dementia.

[41] The method according to

[40] , wherein the neurodegenerative disease is Alzheimer's disease (AD).

[42] The method according to

[40] , wherein the neurodegenerative disease is Parkinson's disease (PD).

[43] The method according to

[40] , wherein the neurodegenerative disease is Huntington's disease (HD).

[44] The method according to

[40] , wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS).

[45] The method of any one of

[33] -

[44] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[46] The method according to any one of

[33] to

[45] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[47] The method according to any one of

[33] to

[45] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[48] ​​The method according to any one of

[33] to

[47] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[49] The method of

[48] , wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[50] The method according to

[48] or

[49] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[51] The method of any one of

[33] to

[50] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[52] The method according to any one of

[33] to

[51] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[53] The method according to any one of

[33] to

[51] , wherein the administered PFKFB3 inhibitor is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) has the structure of formula 1 to formula 53 or formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A to Figure 1C or Figure 1D; (c) has the structure of formula AZ44 to formula AZ70 or formula AZ71, or a salt thereof, as shown in Figure 1E; or (d) is AZ67 or a salt thereof.

[54] The method according to any one of

[33] to

[53] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[55] The method according to any one of

[33] to

[54] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[56] The method according to any one of

[33] to

[55] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of a neurodegenerative disease.

[57] The method according to any one of

[33] to

[56] , wherein treating the neurodegenerative disease includes delaying the onset of the neurodegenerative disease.

[58] The method according to any one of

[33] to

[57] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of a neurodegenerative disease.

[59] A method according to any one of

[33] to

[58] , wherein the method results in the alleviation of one or more symptoms of a neurodegenerative disease in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[60] The method of

[59] , wherein one or more alleviated symptoms of the neurodegenerative disease are indicated by: reduced apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissue; increased survival and / or function of neuronal cells and / or tissue (e.g., neurons); reduced or delayed neurodegeneration; restoration of motor function; reduced long-term damage to neuronal cells / tissue and / or surrounding cells / tissues; reduced inflammation of neuronal cells / tissue; reduced oxidative stress to neuronal cells / tissue; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and increased survival / survival.

[61] The method of

[59] or

[60] , wherein one or more symptoms of the neurodegenerative disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[62] The method of any one of

[59] to

[61] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[63] The method of any one of

[59] to

[62] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[64] The method according to any one of

[33] to

[63] , further comprising administering an additional therapeutic agent to the subject.

[65] A method of treating Alzheimer's disease (AD) in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[66] The method of

[65] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor.

[67] The method of

[65] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor.

[68] The method of

[65] , wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor.

[69] The method according to any one of

[65] to

[68] , wherein the method according to any one of 1(a) to 1(c) is administered as a preventative treatment for Alzheimer's disease.

[70] The method of any one of

[65] -

[68] , wherein the subject has Alzheimer's disease or is at risk of having Alzheimer's disease.

[71] The method of any one of

[65] to

[68] , wherein the subject has Alzheimer's disease or has been diagnosed as having Alzheimer's disease.

[72] The method of any one of

[65] -

[71] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[73] The method according to any one of

[65] to

[72] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[74] The method according to any one of

[65] to

[72] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[75] The method according to any one of

[65] to

[72] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[76] The method of

[75] , wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[77] The method of

[75] or

[76] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[78] The method of any one of

[65] -

[77] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[79] The method according to any one of

[65] to

[78] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[80] The method of any one of

[65] to

[78] , wherein the administered PFKFB3 inhibitor is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) has the structure of formula 1 to formula 53 or formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A to Figure 1C or Figure 1D; (c) has the structure of formula AZ44 to formula AZ70 or formula AZ71, or a salt thereof, as shown in Figure 1E; or (d) AZ67 or a salt thereof.

[81] The method according to any one of

[65] to

[80] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[82] The method according to any one of

[65] to

[81] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[83] The method according to any one of

[65] to

[82] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered before the onset of one or more symptoms of Alzheimer's disease.

[84] The method according to any one of

[65] to

[83] , wherein treating Alzheimer's disease includes delaying the onset of Alzheimer's disease.

[85] The method according to any one of

[65] to

[84] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of Alzheimer's disease.

[86] The method according to any one of

[65] to

[85] , wherein the method results in alleviation of one or more symptoms of Alzheimer's disease in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[87] The method of

[86] , wherein one or more alleviated symptoms of Alzheimer's disease are indicated by reduced apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissue; increased survival and / or function of neuronal cells and / or tissue (e.g., neurons); reduced or delayed neurodegeneration; restoration of motor function; reduced long-term damage to neuronal cells / tissue and / or surrounding cells / tissues; reduced inflammation of neuronal cells / tissue; reduced oxidative stress to neuronal cells / tissue; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and prolonged survival / survival.

[88] The method of

[86] or

[87] , wherein one or more symptoms of Alzheimer's disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[89] The method of any one of

[86] to

[88] , wherein at least one of the subject's behavioral reflexes, balance, coordination, and cognitive function is improved compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[90] The method of any one of

[86] -

[89] , wherein at least one of the subject's cognitive functions is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, or at least one of the following symptoms is reduced in the subject: forgetfulness, difficulty solving simple math problems, difficulty remembering how to do simple tasks, inability to think clearly; difficulty speaking, understanding, reading, or writing; confusion, irritability, mood swings, anxiety, aggression, or tendency to wander away from home, compared to the subject before treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[91] The method according to any one of

[65] to

[90] , further comprising administering an additional therapeutic agent to the subject.

[92] A method of treating Parkinson's disease (PD) in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[93] The method of

[92] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor.

[94] The method of

[92] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor.

[95] The method of

[92] , wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor. The method according to any one of

[92] to

[95] , wherein the method according to any one of

[96] [92(a) to (c)] is administered as a prophylactic treatment for Parkinson's disease.

[97] The method of any one of

[92] to

[95] , wherein the subject has Parkinson's disease or is at risk of having Parkinson's disease.

[98] The method of any one of

[92] to

[95] , wherein the subject has Parkinson's disease or has been diagnosed as having Parkinson's disease.

[99] The method of any one of

[92] -

[98] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0100] The method according to any one of

[92] to

[99] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[0101] The method according to any one of

[92] to

[99] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[0102] The method according to any one of

[92] to

[99] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[0103] The method of any one of claims 1 to 5, wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0104] The method of

[0102] or

[0103] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0105] The method according to any one of

[92] to

[0104] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0106] The method according to any one of

[92] to

[0105] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0107] The method according to any one of

[92] to

[0105] , wherein the PFKFB3 inhibitor administered is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) having the structure of formula 1 to formula 53 or formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A to Figure 1C or Figure 1D; (c) having the structure of formula AZ44 to formula AZ70 or formula AZ71, or a salt thereof, as shown in Figure 1E; or (d) AZ67 or a salt thereof.

[0108] The method according to any one of

[92] to

[0107] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[0109] The method according to any one of

[92] to

[0108] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[0110] The method according to any one of

[92] to

[0109] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered before the onset of one or more symptoms of Parkinson's disease.

[0111] The method according to any one of

[92] to

[0110] , wherein treating Parkinson's disease includes delaying the onset of Parkinson's disease.

[0112] The method according to any one of

[92] to

[0111] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of Parkinson's disease.

[0113] A method according to any one of

[92] to

[0112] , wherein the method results in the alleviation of one or more symptoms of Parkinson's disease in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[0114] The method of any one of the preceding claims, wherein one or more of the alleviated symptoms of Parkinson's disease are indicated by a reduction in apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissues; an increase in survival and / or function of neuronal cells and / or tissues (e.g., neurons); a reduction or delay in neurodegeneration; a restoration of motor function; a reduction in long-term damage to neuronal cells / tissues and / or surrounding cells / tissues; a reduction in inflammation of neuronal cells / tissues; a reduction in oxidative stress to neuronal cells / tissues; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and prolonged survival / survival.

[0115] The method described in

[0113] or

[0114] , wherein one or more symptoms of Parkinson's disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0116] The method according to any one of

[0113] to

[0115] , wherein at least one of the following symptoms: slow movement due to tremors (bradykinesia), muscle rigidity, impaired posture and balance, loss of automatic movements, changes in speech, or difficulty with writing is improved in the subject, as compared to before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0117] The method according to any one of

[0113] to

[0116] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0118] The method according to any one of

[92] to

[0117] , further comprising administering an additional therapeutic agent to the subject.

[0119] 1. A method of treating Huntington's disease (HD) in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0120] The method described in

[0119] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor.

[0121] The method of claim 0119, wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor.

[0122] The method of claim 0119, wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor.

[0123] The method according to any one of [119(a) to (c)], wherein the method according to any one of

[0119] to

[0122] is administered as a prophylactic treatment for Huntington's disease.

[0124] The method according to any one of

[0119] to

[0122] , wherein the subject has Huntington's disease or is at risk of having Huntington's disease.

[0125] The method according to any one of

[0119] to

[0122] , wherein the subject has Huntington's disease or has been diagnosed as having Huntington's disease.

[0126] The method of any one of

[0119] to

[0125] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0127] The method according to any one of

[0119] to

[0126] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[0128] The method according to any one of

[0119] to

[0126] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[0129] The method according to any one of

[0119] to

[0126] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[0130] The method of any one of claims 1 to 5, wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0131] The method according to

[0129] or

[0130] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0132] The method according to any one of

[0119] to

[0131] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0133] The method according to any one of

[0119] to

[0132] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0134] The method according to any one of

[0119] to

[0132] , wherein the PFKFB3 inhibitor administered is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) having the structure of formula 1 to formula 53 or formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A to Figure 1C or Figure 1D; (c) having the structure of formula AZ44 to formula AZ70 or formula AZ71, or a salt thereof, as shown in Figure 1E; or (d) AZ67 or a salt thereof.

[0135] A method according to any one of

[0119] to

[0134] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[0136] The method according to any one of

[0119] to

[0135] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[0137] A method according to any one of

[0119] to

[0136] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered before the onset of one or more symptoms of Huntington's disease.

[0138] The method according to any one of

[0119] to

[0137] , wherein treating Huntington's disease includes delaying the onset of Huntington's disease.

[0139] The method according to any one of

[0119] to

[0138] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of Huntington's disease.

[0140] A method according to any one of

[0119] to

[0139] , wherein the method results in alleviation of one or more symptoms of Huntington's disease in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[0141] The method of any one of the preceding claims, wherein one or more of the symptoms of Huntington's disease are alleviated, as indicated by a reduction in apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissues; an increase in survival and / or function of neuronal cells and / or tissues (e.g., neurons); a reduction or delay in neurodegeneration; a restoration of motor function; a reduction in long-term damage to neuronal cells / tissues and / or surrounding cells / tissues; a reduction in inflammation of neuronal cells / tissues; a reduction in oxidative stress to neuronal cells / tissues; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and an increase in survival / survival duration.

[0142] The method described in

[0140] or

[0141] , wherein one or more symptoms of Huntington's disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0143] The method according to any one of

[0140] to

[0142] , wherein at least one of the subject's cognitive functions is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, or at least one of the following symptoms is alleviated in the subject, as compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor: memory impairment, confusion, impaired judgment, slurred speech, impaired problem-solving ability, personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerking movements and tremors, and dementia.

[0144] The method according to any one of

[0140] to

[0143] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0145] The method according to any one of

[0119] to

[0144] , further comprising administering an additional therapeutic agent to the subject.

[0146] 1. A method of treating neurotrauma in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method, wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0147] The method described in

[0146] , wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor.

[0148] The method of claim 0146, wherein the subject is administered an effective amount of a HIF1-α pathway inhibitor, and the subject has previously been administered a PFKFB3 inhibitor.

[0149] The method of claim 0146, wherein the subject is administered an effective amount of a PFKFB3 inhibitor, and the subject has previously been administered a HIF1-α pathway inhibitor.

[0150] The method according to any one of [146(a)-(c)], wherein the method according to any one of

[0146] -

[0149] is administered as a prophylactic treatment for neurotrauma.

[0151] The method according to any one of

[0146] to

[0149] , wherein the subject is suffering from or at risk of suffering from neurotrauma.

[0152] The method according to any one of

[0146] to

[0149] , wherein the subject is suffering from or has been diagnosed as suffering from neurotrauma.

[0153] The method of any one of

[0146] to

[0153] , wherein the administered HIF1-α pathway inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a dicer substrate, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0154] The method according to any one of

[0146] to

[0153] , wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478 or YC-1, or a salt thereof.

[0155] The method according to any one of

[0146] to

[0153] , wherein the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate or BAY-87-2243, or a salt thereof.

[0156] A method according to any one of

[0146] to

[0153] , wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor.

[0157] The method of any one of claims 1 to 5, wherein the HIF1-α inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0158] The method of

[0156] or

[0157] , wherein the administered HIF1-α inhibitor is the antisense oligonucleotide EZN-2968, or the nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0159] The method according to any one of

[0146] to

[0158] , wherein the administered PFKFB3 inhibitor is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3-binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0160] The method according to any one of

[0146] to

[0159] , wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0161] The method according to any one of

[0146] to

[0159] , wherein the PFKFB3 inhibitor administered is (a) KAN0436151 or KAN0436067, or a salt thereof; (b) having the structure of formula 1 to formula 53 or formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, shown in Figure 1A to Figure 1C or Figure 1D; (c) having the structure of formula AZ44 to formula AZ70 or formula AZ71, or a salt thereof, shown in Figure 1E; or (d) AZ67 or a salt thereof.

[0162] A method according to any one of

[0146] to

[0161] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject.

[0163] The method according to any one of

[0146] to

[0162] , wherein the administration of the HIF1-α pathway inhibitor and / or the PFKFB3 inhibitor is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

[0164] A method according to any one of

[0146] to

[0163] , wherein the neurotrauma is spinal cord injury.

[0165] The method according to any one of

[0146] to

[0163] , wherein the neurotrauma is traumatic brain injury.

[0166] A method according to any one of

[0146] to

[0165] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of neurotrauma.

[0167] A method according to any one of

[0146] to

[0165] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of neurotrauma.

[0168] A method according to any one of

[0146] to

[0167] , wherein treating the neurotrauma includes delaying the onset of the neurotrauma.

[0169] A method according to any one of

[0146] to

[0168] , wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of neurotrauma.

[0170] A method according to any one of

[0146] to

[0169] , wherein the method results in the alleviation of one or more symptoms of neurotrauma in a subject administered a HIF1-α pathway inhibitor and a PFKFB3 inhibitor, compared to the subject before treatment.

[0171] The method of any one of the preceding claims, wherein one or more of the alleviated symptoms of neurotrauma are indicated by a reduction in apoptosis / destruction / loss in number and / or function of neuronal cells and / or tissue; an increase in survival and / or function of neuronal cells and / or tissue (e.g., neurons); a reduction or delay in neurodegeneration; a restoration of motor function; a reduction in long-term damage to neuronal cells / tissue and / or surrounding cells / tissues; a reduction in inflammation of neuronal cells / tissues; a reduction in oxidative stress to neuronal cells / tissues; improved behavioral reflexes, improved cognitive function, improved balance and / or coordination, and an increase in survival / survival duration.

[0172] The method of

[0170] or

[0171] , wherein one or more symptoms of neurotrauma are reduced by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0173] The method according to any one of

[0170] to

[0172] , wherein at least one of the subject's behavioral reflexes, balance, coordination, and cognitive function is improved compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0174] The method according to any one of

[0170] to

[0173] , wherein at least one of the subject's behavioral reflexes, cognitive function, balance, coordination, and cognitive function is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. and / or

[0175] The method according to any one of

[0146] to

[0174] , further comprising administering an additional therapeutic agent to the subject. [Brief description of the drawings]

[0013] [Figure 1A] 1 shows exemplary PFKFB3 small molecule inhibitors. [Figure 1B] 1 shows exemplary PFKFB3 small molecule inhibitors. [Figure 1C] 1 shows exemplary PFKFB3 small molecule inhibitors. [Figure 1D] 1 shows exemplary PFKFB3 small molecule inhibitors. [Figure 1E] 1 shows exemplary PFKFB3 small molecule inhibitors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.Methods and materials similar or equivalent to those described herein can be used in the practice or testing of the compositions provided, but suitable methods and materials are described below.Each publication, patent application, patent, and other references mentioned herein are incorporated herein by reference in their entirety.In case of conflict, the present specification, including definitions, will take precedence.In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0015] Other features and advantages of the disclosed methods and compositions will become apparent from the following disclosure, the drawings, and the claims.

[0016] Whenever embodiments are described herein using the word "comprising," it should be understood that other similar embodiments described in terms of "containing," "consisting of," and / or "consisting essentially of" are also provided. However, when used as transitional phrases within the claims, each must be interpreted separately and within the appropriate legal and factual context (e.g., within the claims, the transitional phrase "comprising" is considered more open-ended, "consisting of" is more exclusive, and "consisting essentially of" is intermediate).

[0017] As used herein, the singular forms "a", "an" and "the" include the plural unless expressly stated or clearly evident from the context that such is not the intention. The singular forms "a", "an" and "the" also include the statistical average composition, characteristics or size of particles within a particle population (e.g., average polyethylene glycol molecular weight, average liposome diameter, average liposome zeta potential). The average particle size and zeta potential of liposomes in a pharmaceutical composition can be routinely measured using methods known in the art, such as dynamic light scattering. The average amount of therapeutic agent in a nanoparticle composition can be routinely measured, for example, using absorption spectroscopy (e.g., ultraviolet-visible spectroscopy).

[0018] As used herein, the term "approximately" or "about" as applied to one or more values ​​of interest refers to a value similar to the stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values ​​that are included within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% in either direction (above or below) of the stated reference value, unless otherwise stated or otherwise clear from the context (except where such number may exceed 100% of the possible values). For example, when used in the context of the amount of a given compound in the lipid component of a nanoparticle composition, "about" can mean + / - 10% of the stated value. For example, a nanoparticle composition that includes a lipid component having about 40% of a given compound can contain 30-50% of that compound.

[0019] The term "and / or," when used herein in phrases such as "A and / or B," is intended to include both A and B, A or B, A (alone), and B (alone). Similarly, the term "and / or," when used in phrases such as "A, B, and / or C," is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0020] The recitation of ranges of values ​​herein, unless otherwise indicated herein, is intended to serve merely as a shorthand method of referring individually to each separate value falling within the range, and each separate value is incorporated herein as if it were individually recited herein.

[0021] When embodiments of the present disclosure are described in terms of a Markush group or other alternative grouping, the compositions or methods of the present disclosure not only encompass the entire group recited as a whole, but also encompass each member of the group individually, and also encompass all possible subgroups of the main group, and also encompass the main group in the absence of one or more of the group members. The methods and compositions of the present disclosure also contemplate the explicit exclusion of any one or more of the group members in the compositions or methods of the present disclosure.

[0022] As used herein, terms such as "antibody" and "antigen-binding antibody fragment" include any protein- or peptide-containing molecule that contains at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one complementarity determining region (CDR) of a heavy or light chain, or an antigen-binding portion thereof.

[0023] The term "antibody" also includes fragments, specified portions and variants thereof, including antibody mimetics or portions of antibodies that mimic the structure and / or function of antibodies or specified fragments or portions thereof, including single chain antibodies, single binding domain antibodies and antigen-binding antibody fragments.

[0024] The term "antibody fragment" refers to a portion of an intact antibody, typically the antigen-binding or variable region of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, single chain (scFv) and Fv fragments, diabodies; linear antibodies; single chain antibody molecules; single Fab arm "one-arm" antibodies, and multispecific antibodies formed from antibody fragments. Antibody fragments include any protein or peptide-containing molecule that includes at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one complementarity determining region (CDR) or ligand-binding portion thereof of a heavy or light chain, a heavy or light chain variable region, a heavy or light chain constant region, a framework region or any portion thereof, or at least a portion of an antigen or antigen receptor or binding protein, which can be incorporated into the antibodies provided herein.

[0025] Antibody fragments can be produced by enzymatic cleavage, synthetically, or recombinantly, as known in the art. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, a combined gene encoding a F(ab')2 heavy chain portion can be designed to include DNA sequences encoding the CH1 domain and / or hinge region of the heavy chain. The various portions of the antibody can be joined together chemically by conventional techniques, or prepared as a contiguous protein using genetic engineering techniques.

[0026] The terms "nucleic acid" or "oligonucleotide" are used interchangeably herein and refer to at least two nucleotides covalently linked together. In some embodiments, the HIF1-α pathway inhibitor and / or PFKFB3 inhibitor administered according to the provided methods is a therapeutic nucleic acid. In some embodiments, the nucleic acid administered is ENMD-1198, shRNA, dicer substrate (e.g., dsRNA), miRNA, anti-miRNA, antisense molecule, decoy, or aptamer, or a plasmid expressing ENMD-1198, shRNA, dicer substrate, miRNA, anti-miRNA, antisense molecule, decoy, or aptamer.

[0027] Nucleic acids administered according to the provided methods are preferably single-stranded or double-stranded and generally contain phosphodiester bonds, although in some cases, nucleic acid / oligonucleotide analogs include those with alternative backbones, including, for example, phosphoramide, phosphorothioate, phosphorodithioate, O-methyl phosphoramidite bonds, as well as peptide nucleic acid backbones and bonds. Other analog nucleic acids / oligonucleotides include those with cationic backbones, non-ionic backbones, and non-ribose backbones. Nucleic acids / oligonucleotides containing one or more carbocyclic sugars are also included in the definition of nucleic acids and oligonucleotides. These modifications of the ribose-phosphate backbone can be made, for example, to facilitate the addition of additional moieties, such as labels, or to increase the stability and half-life of such molecules in physiological environments. The nucleic acid / oligonucleotide backbones of the oligonucleotides used according to the provided methods can range from about 5 nucleotides to about 750 nucleotides. Preferred nucleic acid / oligonucleotide backbones range in length from about 5 nucleotides to about 500 nucleotides, preferably from about 10 nucleotides to about 100 nucleotides.

[0028] The oligonucleotides administered according to the provided methods are polymeric structures of nucleoside and / or nucleotide monomers that can specifically hybridize to at least some region of a nucleic acid target. As described above, the "nucleic acids" and "oligonucleotides" used according to the provided methods include, but are not limited to, compounds that contain naturally occurring bases, sugars and intersugar (backbone) linkages, non-naturally occurring modified monomers that function similarly to their naturally occurring counterparts, or portions thereof (e.g., oligonucleotide analogs or mimetics), and combinations of these naturally occurring and non-naturally occurring monomers. As used herein, the term "modified" or "modification" includes any substitution and / or any change from a starting or natural oligomeric compound such as a nucleic acid. Modifications to nucleic acids include substitutions or changes to internucleoside linkages, sugar moieties, or base moieties, such as those described herein and otherwise known in the art.

[0029] As used herein, "small molecule" refers to an organic compound that is synthesized by conventional organic chemistry methods (e.g., in a laboratory) or found in nature. Typically, small molecules are characterized by containing several carbon-carbon bonds and having a molecular weight of less than about 1500 grams / mole. In certain embodiments, small molecules are less than about 1000 grams / mole. In certain embodiments, small molecules are less than about 550 grams / mole. In certain embodiments, small molecules are between about 200 and about 550 grams / mole. In certain embodiments, small molecules do not include peptides (e.g., compounds that include two or more amino acids joined by peptidyl bonds). In certain embodiments, small molecules do not include nucleic acids.

[0030] The terms "condition" and "disease" are used interchangeably herein.

[0031] As used herein, the term "neurological disease" generally refers to a disease or condition that causes or is associated with damage to neural cells / tissues. Such damage may be the result of, for example, degeneration of neural tissue, physical trauma to neural tissue, and / or inflammation / oxidative stress within neural tissue. The term "neurological disease progression" refers to the gradual worsening of a disease over time, whereby symptoms and neurochemical deficits become increasingly debilitating and / or intense. Neurological disease progression is often correlated with a decline in brain tissue structure, activity, and / or function. As used herein, the term "inhibiting neurological disease progression" refers to slowing and / or halting the progression of neurological disease symptoms and neurochemical deficits.

[0032] In another embodiment, the method of inhibiting progression of a neurological disease further comprises administering a second active pharmaceutical ingredient effective in treating the neurological disease.

[0033] As used herein, the term "neurodegenerative disease" refers to a disease characterized by a progressive decline in structure, activity, and / or function of neural tissue, including brain tissue. Exemplary neurodegenerative diseases that can be treated according to the provided methods include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, frontotemporal lobar degeneration, and dementia (e.g., senile dementia of the AD type (SDAT), vascular dementia, or dementia with Lewy bodies).

[0034] As used herein, the term "neurodegenerative disease progression" refers to the gradual worsening of the disease over time, resulting in increasingly debilitating and / or intense symptoms and neurochemical deficits. Neurodegenerative disease progression is often correlated with a decline in brain tissue structure, activity, and / or function. The term "inhibiting neurodegenerative disease progression" refers to slowing and / or halting the progression of neurodegenerative disease symptoms and / or neurochemical deficits. As used herein, "delaying the onset" of a neurological disease, such as AD, PD, HD, ALS, and dementia, means delaying, preventing, slowing, delaying, stabilizing, and / or prolonging the onset of one or more symptoms of the disease, including slowing the rate at which the disease progresses in a subject (e.g., transitioning a subject from a rapidly progressing disease to a more slowly progressing disease). This delay can be of different lengths of time depending on the medical and / or medical history of the subject being treated. A sufficient or significant delay can, in effect, encompass prevention, in that the subject does not develop detectable disease. A method that "delays" the onset of a disease is a method that reduces the extent of the disease within a given time frame compared to when the method is not used. Such comparisons are typically based on clinical studies using a statistically significant number of subjects, but this knowledge can be based on anecdotal evidence. "Delaying onset" can mean that the extent of clinical symptoms and / or undesirable clinical symptoms of a neurological disease are reduced and / or the time course of progression is slowed or extended compared to when the drug is not administered. Thus, "delaying onset" also includes, but is not limited to, the alleviation of symptoms, whether detectable or undetectable, the reduction in extent, the stabilization of disease pathology (i.e., not worsening), the delay or slowing of disease progression, and remission (whether partial or complete).

[0035] The terms "neurotrauma," "neurogenic trauma," and "neural injury" are used interchangeably herein and refer to mechanical injury to the brain or spinal cord. The terms "injury caused by neurotrauma" or "neurotrauma-induced injury" refer to injury caused by mechanical injury to the brain or spinal cord.

[0036] References herein to spinal cord injury (SCI) include any form of physical, chemical, or genetic trauma to the spinal cord. Physical trauma includes tissue damage, such as abrasions, incisions, contusions, punctures, compression, etc., that may result from traumatic contact of any part of the head, neck, or spinal column, or any part associated / adjacent thereto, with a foreign body. Other forms of traumatic injury may result from constriction or compression of central nervous system (CNS) tissue due to inappropriate accumulation of fluid (e.g., blockage or dysfunction of normal cerebrospinal or vitreous humor production, turnover, volume regulation; or subdural or intracranial hematoma or edema). Similarly, traumatic constriction or compression may result from the presence of a mass of abnormal tissue, such as a metastatic or primary tumor, or disease (e.g., poliomyelitis, spina bifida, Friedreich's ataxia, etc.). In some embodiments, the methods and compositions provided herein are useful for treating or preventing secondary injury resulting from an initial insult / injury to the CNS (e.g., spinal cord).

[0037] As used herein, the term "stroke" refers to the sudden death of brain cells due to lack of oxygen when blood flow to the brain is compromised by a blocked or ruptured artery to the brain. Risk factors associated with increasing the likelihood of stroke include older age, high blood pressure, previous stroke or transient ischemic attack, diabetes, high cholesterol, smoking, and atrial fibrillation.

[0038] As used herein, an "effective amount" refers to a dose of an agent sufficient to provide a medically desirable prophylactic and / or therapeutic effect against a neurological disorder (e.g., neuropathy, neurodegenerative disorders such as AD, PD, HD, ALS, dementia, neuronal damage such as cerebral ischemia, or spinal cord injury) or against neuronal cells and / or tissues (e.g., CNS tissues such as the brain or spinal cord). The effective amount will vary depending on the desired outcome, the particular neurological disorder being treated (or prevented), the age and physical condition of the subject being treated, the severity of the condition, the duration of treatment, the nature of concurrent or concomitant treatments (if any), the particular route of administration, and similar factors within the knowledge and skill of the medical practitioner.

[0039] An "effective amount" can be determined empirically and in a routine manner in relation to a given purpose. Preventive and / or therapeutic effects include, but are not limited to, reducing apoptosis / destruction / loss of number and / or function of nerve cells and / or tissues; increasing survival of nerve cells and / or tissues (e.g., neurons); reducing or delaying neurodegeneration; restoring motor function; reducing long-term damage to nerve cells / tissues and / or surrounding cells / tissues; reducing inflammation of nerve cells / tissues; reducing oxidative stress of nerve cells / tissues; improving behavioral reflexes, improving cognitive function, and prolonging survival / life span.

[0040] The terms "subject," "patient," "individual," and "animal" are used interchangeably and refer to mammals, such as human patients and non-human primates, as well as laboratory animals, such as rabbits, rats, and mice, and other laboratory animals. Animals include all vertebrates, e.g., mammals and non-mammals, such as chickens, amphibians, and reptiles. As used herein, "mammal" refers to any member of the class Mammalia, including, but not limited to, humans and non-human primates, such as chimpanzees and other ape and monkey species; farm animals, such as cows, sheep, pigs, goats, and horses; domesticated mammals, such as dogs and cats; laboratory animals, including rodents, such as mice, rats, and guinea pigs; and other members of the class Mammalia known in the art. In certain embodiments, the patient is a human.

[0041] The terms "treat" or "treatment," "treating," or "therapy" and the like refer to both (a) therapeutic measures that cure, slow, attenuate, alleviate the symptoms of, and / or halt the progression of, a pathological condition, and (b) prophylactic or preventative measures that prevent and / or delay the onset of the targeted condition and / or its associated symptoms.

[0042] Thus, subjects in need of treatment include those already suffering from a neurological disease, those at risk of suffering from a neurological disease, and those in whom a neurological disease should be prevented. A subject can be routinely identified as "suffering from or at risk of suffering from" a neurological disease and / or another disease referred to herein using medical and diagnostic techniques known in the art. In certain embodiments, a subject is successfully "treated" according to the provided methods, for example, when the subject shows a total, partial, or transient remission or disappearance of symptoms associated with a disease (e.g., a neurodegenerative disorder such as AD, PD, HD, ALS, or dementia, or a neurological injury such as a spinal cord injury). In certain embodiments, the terms "treat" or "treatment", "treating", or "therapy" refer to an improvement in at least one measurable physical parameter of a neurological disease, such as improvement of cognitive symptoms or protection of nerve cells. In other embodiments, the terms "treat" or "treatment", "treating" or "therapy" refer to inhibiting the progression of a neurological disease, either physically (e.g., stabilization of a discernible symptom), physiologically (e.g., stabilization of a physical parameter), or both. In other embodiments, the terms "treat" or "treatment", "treating" or "therapy" refer to alleviating symptoms, reducing inflammation, inhibiting cell death, and / or restoring cellular function. Treatment can be performed with the HIF1-α pathway inhibitor and PFKFB3 inhibitor compositions disclosed herein or in further combination with one or more additional therapeutic agents.

[0043] The term "pharmaceutical acceptable carrier" refers to an ingredient in a pharmaceutical preparation other than active ingredient that is non-toxic to subjects. Pharmaceutically acceptable carriers include, but are not limited to, buffers, carriers, excipients, stabilizers, diluents or preservatives. Pharmaceutically acceptable carriers can include, for example, one or more compatible solid or liquid fillers, diluents or encapsulating materials suitable for administration to humans or other subjects.

[0044] The "therapeutic agent(s)" used in accordance with the disclosed methods and compositions can further include any agent for treating a condition in a subject.

[0045] PFKFB3 inhibitors PFKFB3 (6-phosphofructo-2-kinase-fructose-2,6-bisphosphatase 3) is a bifunctional protein involved in both the synthesis and degradation of fructose-2,6-bisphosphate, a regulatory molecule that controls eukaryotic glycolysis and is required for cell cycle progression and prevention of apoptosis.

[0046] In some embodiments, the present disclosure provides a method of treating a neurological disease in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor or a HIF1-α inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor or a HIF1-α inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor or a HIF1-α inhibitor; The method provides said wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0047] The PFKFB3 inhibitor that can be used according to the provided method is not particularly limited.In some embodiments, the PFKFB3 inhibitor administered is an antibody or PFKFB3 binding antibody (e.g., single chain antibody, single domain antibody, Fab fragment, F(ab')2 fragment, Fd fragment, Fv fragment, scFv, dAb fragment, or another engineered molecule, such as diabody, triabody, tetrabody, minibody, and minimal recognition unit), a nucleic acid molecule (e.g., aptamer, antisense molecule, ribozyme, dicer substrate, miRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 inhibitory binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0048] In some embodiments, the PFKFB3 inhibitor administered according to the provided methods has a concentration of PFKFB3 activity with an IC50 of 100 μM or less for PFKFB3 activity / function. In some embodiments, the PFKFB3 inhibitor has an IC50 of at least or up to about 200, 100, 80, 50, 40, 20, 10, 5 or 1 μM, or at least or up to about 100, 10 or 1 nM or less (or any range or value derivable therein). In some embodiments, the PFKFB3 inhibitor inhibits the expression of PFKFB3. Assays for determining the ability of a compound to inhibit PFKFB3 activity are known in the art. In some embodiments, the inhibition of PFKFB3 activity or expression is a decrease compared to a control level or sample. In some embodiments, a functional assay such as an MTT assay, a cell proliferation assay, a BRDU or Ki67 immunofluorescence assay, an apoptosis assay or a glycolysis assay is used to assay the ability of the composition to inhibit PFKFB3 activity.

[0049] In some embodiments, the PFKFB3 inhibitor administered according to the provided methods is an antibody or a PFKFB3-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit). In certain embodiments, the PFKFB3 inhibitor administered is a nanobody (e.g., a VHH).

[0050] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is an aptamer, an antisense molecule, a ribozyme, a dicer substrate, miRNA, dsRNA, ssRNA, and shRNA. In certain embodiments, the HIF1-α inhibitor administered according to the provided methods is an siRNA or an antisense oligonucleotide.

[0051] Representative examples of human PFKFB3 coding sequences are provided in GenBank Accession Nos. NM_004566.3, NM_001145443.2, NP_001138915.1, NM_001282630.2, NM_001314063.1, NM_001323016.1, NM_001323017.1, and NM_001363545.2. The sequences associated with each of these Genbank Accession Nos. are incorporated herein by reference in their entirety for all purposes. Therapeutic nucleic acids that inhibit PFKFB3 activity can be routinely designed and prepared based on each of the above human PFKFB3 transcript sequences using methods known in the art.

[0052] Certain embodiments of the provided methods contemplate administration of a PFKFB3 inhibitory nucleic acid or any method of inhibiting gene expression of PFKFB3 known in the art. Examples of inhibitory nucleic acids include, but are not limited to, antisense nucleic acids such as ENMD-1198 (small interfering RNA), small hairpin RNA (shRNA), double-stranded RNA, and any other antisense oligonucleotides. Also included are ribozymes or nucleic acids encoding any of the inhibitors described herein. The inhibitory nucleic acid may inhibit transcription of PFKFB3 in cells or prevent translation of PFKFB3 gene transcripts. In some embodiments, the PFKFB3 inhibitory nucleic acid administered according to the provided methods is between 16 and 1000 nucleotides in length. In certain embodiments, the PFKFB3 inhibitory nucleic acid administered is between 18 and 100 nucleotides in length. In certain embodiments, the PFKFB3 inhibitory nucleic acid administered is at least or up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 50, 60, 70, 80, 90 nucleotides, or any range derivable therein.

[0053] In some embodiments, the PFKFB3 inhibitory nucleic acid administered according to the provided methods can reduce expression of PFKFB3 by at least 10%, 20%, 30% or 40%, more particularly at least 50%, 60%, or 70%, most particularly at least 75%, 80%, 90%, 95% or more, or any range or value therebetween.

[0054] In some embodiments, the PFKFB3 inhibitory nucleic acid administered in accordance with the provided methods is 17-25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of mature PFKFB3 mRNA (e.g., a sequence disclosed in any one or more of GenBank Accession Nos. NM_004566.3, NM_001145443.2, NM_001282630.2, NM_001314063.1, NM_001323016.1, NM_001323017.1, and NM_001363545.2). In some embodiments, the PFKFB3 inhibitory nucleic acid administered is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. In some embodiments, the PFKFB3 inhibitory nucleic acid administered has a sequence (5' to 3') that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary to the corresponding 5' to 3' sequence of mature PFKFB3 mRNA (e.g., a sequence disclosed in any one or more of GenBank Accession Nos. NM_004566.3, NM_001145443.2, NM_001282630.2, NM_001314063.1, NM_001323016.1, NM_001323017.1, and NM_001363545.2), or any range derivable therein. One skilled in the art could use the portion of the probe sequence that is complementary to the sequence of the mature mRNA as the sequence of the mRNA inhibitor, and furthermore, that portion of the probe sequence could be altered so that it is still 90% complementary to the sequence of the mature mRNA.

[0055] In some embodiments, the PFKFB3 inhibitory nucleic acid administered according to the provided methods is a miRNA. In further embodiments, the administered miRNA is hsa-mir-26b-5p (MIRT028775), hsa-mir-330-3p (MIRT043840), hsa-mir-6779-5p (MIRT454747), hsa-mir-6780a-5p (MIRT454748), hsa-mir-3689c (MIRT454749), hsa-mir-3689b-3p (MIRT454749), hsa-mir-3689c-3p ...c-3p (MIRT454749), hsa-mir-3689b-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa-mir-3689c-3p (MIRT454749), hsa p(MIRT454750), hsa-mir-3689a-3p(MIRT454751), hsa-mir-30b-3p(MIRT454752), hsa-mir-1273h-5p( MIRT454753), hsa-mir-6778-5p(MIRT454754), hsa-mir-1233-5p(MIRT454755), hsa-mir-6799-5p(MIRT 454756), hsa-mir-7106-5p(MIRT454757), hsa-mir-6775-3p(MIRT454758), hsa-mir-1291(MIRT454759 ), hsa-mir-765(MIRT454760), hsa-mir-423-5p(MIRT454761), hsa-mir-3184-5p(MIRT454762), hsa-mi A member selected from r-6856-5p (MIRT454763), hsa-mir-6758-5p (MIRT454764), hsa-mir-3185 (MIRT527973), hsa-mir-6892-3p (MIRT527974), hsa-mir-6840-5p (MIRT527975), and hsa-mir-6865-3p (MIRT527976).

[0056] In some embodiments, the PFKFB3 inhibitor administered according to the provided method is a small molecule.The small molecule PFKFB3 inhibitor administered can be any small molecule that is determined to inhibit the function or activity of PFKFB3.Such small molecules can be determined based on in vitro or in vivo functional assays.

[0057] In some embodiments, the PFKFB3 inhibitor small molecule administered according to the provided methods is a small molecule PFKFB3 inhibitor molecule disclosed in U.S. Patent Publication Nos. 20130059879, 20120177749, 20100267815, 20100267815, and 20090074884, the disclosures of each of which are incorporated by reference in their entireties herein.

[0058] In some embodiments, the PFKFB3 inhibitor administered in accordance with the provided methods is (1H-benzo[g]indol-2-yl)-phenyl-methanone, (3H-benzo[e]indol-2-yl)-phenyl-methanone, (3H-benzo[e]indol-2-yl)-(4-methoxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-pyridin-4-yl-methanone, the HCl salt of (3H-benzo[e]indol-2-yl)-pyridin-4-yl-methanone, (3H-benzo[e]indol-2-yl)-pyridin-4-yl-methanone, (3H-benzo[e]indol-2-yl) -(3-Methoxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-pyridin-3-yl-methanone, (3H-benzo[e]indol-2-yl)-(2-methoxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-(2-hydroxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-(4-hydroxy-phenyl)-methanone, (5-methyl-3H-benzo[e]indol-2-yl)-phenyl-methanone, phenyl-(7H-pyrrolo[2,3-h]quinoline-8 -yl)-methanone, (3H-benzo[e]indol-2-yl)-(3-hydroxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-(2-chloro-pyridin-4-yl)-methanone, (3H-benzo[e]indol-2-yl)-(1-oxy-pyridin-4-yl)-methanone, phenyl-(6,7,8,9-tetrahydro-3H-benzo[e]indol-2-yl)-methanone, (3H-benzo[e]indol-2-yl)-(4-hydroxy-3-methoxyrutheny)-methanone, (3H-benzo[e]indol-2-yl)-(4-hydroxy-3-methoxyrutheny)-methanone, e]indol-2-yl)-(4-benzyloxy-3-methoxy-phenyl)-methanone, 4-(3H-benzo[e]indole-2-carbonyl)-benzoic acid methyl ester, 4-(3H-benzo[e]indole-2-carbonyl)-benzoic acid, (4-amino-phenyl)-(3H-benzo[e]indol-2-yl)-methanone, 5-(3H-benzo[e]indole-2-carbonyl)-2-benzyloxy-benzoic acid methyl ester, 5-(3H-benzo[e]indole-2-carbonyl)-2-benzyloxy-benzoic acid methanone,(3H-benzo[e]indol-2-yl)-(2-methoxy-pyridin-4-yl)-methanone, (5-fluoro-3H-benzo[e]indol-2-yl)-(3-methoxy-phenyl)-methanone, (5-fluoro-3H-benzo[e]indol-2-yl)-pyridin-4-yl-methanone, (4-benzyloxy-3-methoxy-phenyl)-(5-fluoro-3H-benzo[e]indol-2-yl)-methanone, (5-fluoro-3H-benzo[e]indol-2-yl)-(4-hydroxy-3-methoxy- phenyl)-methanone, (3H-benzo[e]indol-2-yl)-(3-hydroxymethyl-phenyl)-methanone, cyclohexyl-(5-fluoro-3H-benzo[e]indol-2-yl)-methanone, (5-fluoro-3H-benzo[e]indol-2-yl)-(3-fluoro-4-hydroxy-phenyl)-methanone, (3H-benzo[e]indol-2-yl)-p-tolyl-methanone, (3H-benzo[e]indol-2-yl)-(3-methoxy-phenyl-methanol, (3H-benzo[e]indol (4-amino-3-methoxy-phenyl)-(3H-benzo[e]indol-2-yl)-pyridin-4-yl-methanol, 3H-benzo[e]indole-2-carboxylic acid phenylamide, 3H-benzo[e]indole-2-carboxylic acid (3-methoxy-phenyl)-amide, (3H-benzo[e]indol-2-yl)-(4-dimethylamino-phenyl)-methanone, (4-amino-3-methoxy-phenyl)-(3H-benzo[e]indol-2-yl)-methanone, (4-amino-3-methoxy-phenyl)-(5-hydroxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-3-methoxy-phenyl)-(5-methoxy-3H-benzo[e]indol-2-yl)-methanone, N-[4-(3H-benzo[e]indole-2-carbonyl)-phenyl]-methanesulfonamide, 3H-benzo[e]indole-2-carboxylic acid (4-amino-phenyl)-amide, (4-amino-phenyl)-(5-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-2-fluoro-phenyl)-(5-methoxy-3H-benzo[e]indol-2-yl)-methanone,(4-amino-3-fluoro-phenyl)-(5-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-2-methoxy-phenyl)-(5-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-phenyl)-(9-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-3-methoxy-phenyl)-(9-methoxy-3H-benzo[e]indol-2-yl)-methanone Methanone, (4-amino-2-methoxy-phenyl)-(9-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-3-fluoro-phenyl)-(9-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-2-fluoro-phenyl)-(9-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-3-fluoro-phenyl)-(3H-benzo[e]indol-2-yl )-methanone, (4-amino-2-fluoro-phenyl)-(3H-benzo[e]indol-2-yl)-methanone, (4-amino-phenyl)-(7-methoxy-3H-benzo[e]indol-2-yl)-methanone, (4-amino-phenyl)-(5-hydroxy-3-methyl-3H-benzo[e]indol-2-yl)-methanone, (7-amino-5-fluoro-9-hydroxy-3H-benzo[e]indol-2-yl)-(3-methyl- pyridin-4-yl)-methanone, (5-amino-3H-pyrrolo[3,2-f]isoquinolin-2-yl)-(3-methoxy-pyridin-4-yl)-methanone, (4-amino-2-methyl-phenyl)-(9-hydroxy-3H-pyrrolo[2,3-c]quinolin-2-yl)-methanone, and (4-amino-phenyl)-(7-methanesulfonyl-3H-benzo[e]indol-2-yl)-methanone, or at least one of their salts.

[0059] In some embodiments, the PFKFB3 inhibitor administered in accordance with the provided methods is 1-pyridin-4-yl-3-quinolin-4-yl-propenone, 1-pyridin-4-yl-3-quinolin-3-yl-propenone, 1-pyridin-3-yl-3-quinolin-2-yl-propenone, 1-pyridin-3-yl-3-quinolin-4 ... 3-yl-propenone, 1-naphthalen-2-yl-3-quinolin-2-yl-propenone, 1-naphthalen-2-yl-3-quinolin-3-yl-propenone, 1-pyridin-4-yl-3-quinolin-3-yl-propenone, 3-(4-hydroxy-quinolin-2-yl)-1-pyridin-4-yl-propenone, 3-(8-hydroxy-quinolin-2-yl)-1-pyridin-3-yl-propenone 3-quinolin-2-yl-1-p-tolyl-propenone, 3-(8-hydroxy-quinolin-2-yl)-1-pyridin-4-yl-propenone, 3-(8-hydroxy-quinolin-2-yl)-1-p-tolyl-propenone, 3-(4-hydroxy-quinolin-2-yl)-1-p-tolyl-propenone, 1-phenyl-3-quinolin-2-yl-propenone, 1-pyridin-2-yl In one embodiment, the quinolin-2-yl-propenone is at least one of 1-(2-hydroxy-phenyl)-3-quinolin-2-yl-propenone, 1-(4-hydroxy-phenyl)-3-quinolin-2-yl-propenone, 1-(2-amino-phenyl)-3-quinolin-2-yl-propenone, 1-(4-amino-phenyl)-3-quinolin-2-yl-propenone, or a salt thereof.

[0060] In some embodiments, the PFKFB3 inhibitor administered in accordance with the provided methods is 4-(3-quinolin-2-yl-acryloyl)-benzamide, 4-(3-quinolin-2-yl-acryloyl)-benzoic acid, 3-(8-methyl-quinolin-2-yl)-1-pyridin-4-yl-propenone, 1-(2-fluoro-pyridin-4-yl)-3-quinolin-2-yl-propenone, 3-(8-fluoro-quinolin-2-yl)-1-pyridinyl and at least one of 1-methyl-4-[3-(8-methyl-quinolin-2-yl)-acryloyl]-pyridinium, or a salt thereof.

[0061] In some embodiments, the PFKFB3 inhibitor administered according to the provided methods is PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), (2S)-N-[4-[[3-cyano-1-(2-methyl-propyl)-1H-indol-5-yl]oxy]phenyl]-2-pyrrolidine-carboxamide 3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one), (2S)-N-[4-[[3-cyano-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-1H-indol-5-yl]oxy]phenyl]-2-pyrrolidine-carboxamide, and ethyl 7-hydroxy-2-oxo-2H-1-benzopyran-3-carboxylate, or a salt thereof.

[0062] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is PFK15 or a salt thereof.

[0063] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is PFK158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0064] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), or a salt thereof.

[0065] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is AZ67, or a salt thereof.

[0066] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided is at least one PFKFB3 inhibitor having the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or ID. In other embodiments, the PFKFB3 inhibitor administered according to the methods provided is a PFKFB3 inhibitor having the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0067] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is KAN0436151, or a salt thereof.

[0068] In certain embodiments, the PFKFB3 inhibitor administered in accordance with the methods provided is KAN0436067, or a salt thereof.

[0069] HIF1-α pathway inhibitors Hypoxia-inducible factor 1-α (HIF-1-α) is a subunit of the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1), which is thought to be the master transcriptional regulator of the cellular and developmental response to hypoxia.

[0070] In some embodiments, the present disclosure provides a method of treating a neurological disease in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor or a HIF1-α inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor or a HIF1-α inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to a subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor or a HIF1-α inhibitor; The method provides said wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0071] In further embodiments, the neurological disease treated in accordance with the methods provided herein is a neurodegenerative disease, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), or neurotrauma.

[0072] As used herein, the term "HIF1-α pathway-α inhibitor" refers to a composition that inhibits or reduces HIF1-α directly or indirectly through inhibiting one or more activities of the PI3K / AKT / mTOR pathway upstream of the HIF1-α pathway. The term "HIF1-α inhibitor" is used herein to refer to a composition that directly inhibits or reduces HIF1-α. Thus, for example, mTOR pathway inhibitors such as temsirolimus, everolimus, and sirolimus are considered "HIF1-α pathway-α inhibitors" and not "HIF1-α inhibitors" herein.

[0073] The "HIF1-α pathway-α inhibitor" that can be administered according to the provided method is not particularly limited. In some embodiments, the administered HIF1-α pathway inhibitor is an antibody or HIF1-α binding antibody fragment (e.g., single chain antibody, single domain antibody (e.g., VHH), Fab fragment, F(ab')2 fragment, Fd fragment, Fv fragment, scFv, dAb fragment, or another engineered molecule, e.g., diabody, triabody, tetrabody, minibody, and minimal recognition unit), a nucleic acid molecule (e.g., aptamer, antisense molecule, ribozyme, dicer substrate, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0074] In some embodiments, the administered HIF1-α pathway inhibitor administered according to the provided method is at a concentration of HIF1-α activity / function IC50 of 100 μM or less. In some embodiments, the HIF1-α pathway inhibitor has an IC50 of at least or up to about 200, 100, 80, 50, 40, 20, 10, 5 or 1 μM, or at least or up to about 100, 10 or 1 nM or less (or any range or value derivable therein). In some embodiments, the HIF1-α pathway inhibitor inhibits the expression of HIF1-α. Assays for determining the ability of a compound to inhibit HIF1-α activity are known in the art. In some embodiments, the inhibition of HIF1-α activity or expression is a decrease compared to a control level or sample. In some embodiments, a functional assay such as an MTT assay, a cell proliferation assay, a BRDU or Ki67 immunofluorescence assay, an apoptosis assay or a glycolysis assay is used to assay the ability of the composition to inhibit HIF1-α activity.

[0075] The HIF1-α inhibitor that can be administered according to the provided method is not particularly limited. In some embodiments, the HIF1-α inhibitor modulates one or more of HIF-1α mRNA expression, HIF-1α protein translation or degradation, HIF-1α / HIF-1β dimerization, HIF-1α-DNA binding (e.g., HIF-1α / HRE), and / or HIF-1α transcriptional activity (e.g., CH-1 of p300 / C-TAD of HIF-1α).

[0076] In some embodiments, the HIF1-α inhibitor administered according to the provided method is a small molecule.In some embodiments, the HIF1-α inhibitor administered according to the provided method is a protein or polypeptide (e.g., anti-HIF1 antibody or antibody fragment that binds to HIF1).In some embodiments, the HIF1-α inhibitor administered according to the provided method is a therapeutic nucleic acid (e.g., aptamer, antisense molecule, ribozyme, dicer substrate, siRNA, miRNA, dsRNA, ssRNA, or shRNA).

[0077] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the provided methods is a HIF1-α pathway inhibitor (e.g., a PI3K pathway inhibitor, a MAPK pathway inhibitor, an Akt pathway inhibitor, and / or an mTOR inhibitor); a HIF translation inhibitor (e.g., a topoisomerase inhibitor, a microtubule targeting drug, a cardiac glycoside, or an antisense HIF-1a mRNA); an inhibitor of HIF stability, nuclear localization or dimerization (e.g., acriflavine or an HDAC inhibitor); an inhibitor of HIF transactivation (e.g., a HIF1 coactivator recruitment inhibitor or a HIF1 DNA binding inhibitor).

[0078] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a HIF1-α pathway inhibitor (e.g., a PI3K pathway inhibitor, a MAPK pathway inhibitor, an Akt pathway inhibitor, and / or an mTOR inhibitor). In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a PI3K pathway inhibitor. In one embodiment, the HIF1-α pathway inhibitor administered is P3155, LY29, LY294002, wortmannin, or GDC-0941. In one embodiment, the HIF1-α pathway inhibitor administered is resveratrol. In another embodiment, the HIF1-α pathway inhibitor administered is glyceollin. In some embodiments, the HIF1-α pathway inhibitor administered according to the provided methods is an mTOR inhibitor. In one embodiment, the HIF1-α pathway inhibitor administered is rapamycin, temsirolimus (CC1-779), everolimus, sirolimus, or PP242.

[0079] In certain embodiments, the HIF1-α inhibitor administered is silibinin.

[0080] In some embodiments, the HIF1-α inhibitor administered according to the provided method is a HIF translation inhibitor.In one embodiment, the HIF1-α inhibitor administered is PX-478 (S-2-amino-3-[4'-N,N-bis(chloroethyl)[amino]phenylpropionic acid N-oxide dihydrochloride), NSC-64421, camptothecin (CPT), SN38, irinotecan, topotecan, NSC-644221, cycloheximide, or apigenin, or their salts. In one embodiment, the HIF1-α inhibitor administered is aminoflavone, KC7F2 (N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(2,5-dichlorobenzenesulfonamide), 2-methoxyestradiol (2ME2), or an analog or salt thereof. In one embodiment, the HIF1-α inhibitor administered is ENMD-1198, ENMD-1200, or ENMD-1237, or a salt thereof. In one embodiment, the HIF1-α inhibitor administered is EZN-2208, or a salt thereof.

[0081] In a particular embodiment, the HIF1-α inhibitor administered is PX-478 or a salt thereof.

[0082] In some embodiments, the HIF1-α inhibitor administered according to the provided method is a cardiac glycoside. In one embodiment, the cardiac glycoside administered is digoxin or a salt thereof. In another embodiment, the cardiac glycoside administered is ouabain or proscillaridin A or a salt thereof.

[0083] In some embodiments, the HIF1-α pathway inhibitor administered according to the provided method is a topoisomerase inhibitor.In one embodiment, the topoisomerase inhibitor administered is camptothecin (CPT), SN38, irinotecan, or topotecan (e.g., PEG-SN38), or salts thereof.

[0084] In some embodiments, the HIF1-α pathway inhibitor administered according to the provided method is a microtubule targeting drug.In one embodiment, the microtubule targeting drug administered is 2 methoxyestradiol (2ME2), ENMD-1198, ENMD-1200, ENMD-1237, or taxotere, or their salts.

[0085] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is an aptamer, an antisense molecule, a ribozyme, a dicer substrate, an siRNA, an miRNA, a dsRNA, a ssRNA, and an shRNA. In some embodiments, the therapeutic nucleic acid is an antisense oligonucleotide.

[0086] In certain embodiments, the HIF1-α inhibitor administered according to the provided methods is an siRNA or an antisense oligonucleotide.In one embodiment, the HIF1-α inhibitor administered is EZN-2968.In one embodiment, the HIF1-α inhibitor administered is RX-0047.

[0087] Representative examples of human HIF1-A coding sequences are provided in GenBank Accession Nos. NM_004566.3, NM_001145443.2, NP_001138915.1, NM_001282630.2, NM_001314063.1, NM_001323016.1, NM_001323017.1, and NM_001363545.2. The sequences associated with each of these Genbank Accession Nos. are incorporated herein by reference in their entirety for all purposes. Therapeutic nucleic acids that inhibit HIF1-A activity can be routinely designed and prepared based on each of the above human HIF1-A transcript sequences using methods known in the art.

[0088] Certain embodiments of the provided methods contemplate administration of HIF1-A inhibitory nucleic acid or any method of inhibiting gene expression of HIF1-A known in the art. Examples of inhibitory (therapeutic) nucleic acids include, but are not limited to, antisense nucleic acids such as ENMD-1198 (small interfering RNA), small hairpin RNA (shRNA), double-stranded RNA, and any other antisense oligonucleotides. Also included are ribozymes or nucleic acids encoding any of the inhibitors described herein. The inhibitory nucleic acid may inhibit transcription of HIF1-A in cells or prevent translation of HIF1-A gene transcripts. In some embodiments, the HIF1-A inhibitory nucleic acid administered according to the provided methods is between 16 and 1000 nucleotides in length. In certain embodiments, the HIF1-A inhibitory nucleic acid administered is between 18 and 100 nucleotides in length. In certain embodiments, the HIF1-A inhibitory nucleic acid administered is at least or up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 50, 60, 70, 80, 90 nucleotides, or any range derivable therein.

[0089] In some embodiments, the HIF1-A inhibitory nucleic acid administered in accordance with the provided methods can reduce expression of HIF1-A by at least 10%, 20%, 30% or 40%, more particularly at least 50%, 60%, or 70%, and most particularly at least 75%, 80%, 90%, 95% or more, or any range or value therebetween.

[0090] In some embodiments, the HIF1-A inhibitory nucleic acid administered in accordance with the provided methods is 17-25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of mature HIF1-A mRNA (e.g., as disclosed in any one or more of GenBank Accession Nos. NM_001530.4, NM_181054.3, and NM_001243084.2). In some embodiments, the HIF1-A inhibitory nucleic acid administered is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. In some embodiments, the administered HIF1-A inhibitory nucleic acid has a sequence (5' to 3') that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary to the corresponding 5' to 3' sequence of the mature HIF1-A mRNA (e.g., as disclosed in any one or more of GenBank Accession Nos. NM_001530.4, NM_181054.3, and NM_001243084.2), or any range derivable therein. One of skill in the art would be able to use the portion of the probe sequence that is complementary to the sequence of the mature mRNA as the sequence of the mRNA inhibitor. Furthermore, that portion of the probe sequence can be modified so that it is still 90% complementary to the sequence of the mature mRNA.

[0091] In some embodiments, the HIF1-α inhibitory nucleic acid administered according to the provided methods is an miRNA mimic. In some embodiments, the HIF1-α inhibitor administered is an miR-483 mimic.

[0092] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is an inhibitor of HIF stability, nuclear localization or dimerization. In one embodiment, the inhibitor administered according to the provided methods destabilizes HIF. In one embodiment, the inhibitor administered according to the provided methods is a histone deacetylase inhibitor (HDACI). In further embodiments, the HDACI administered is LW6 / CAY10585, vorinostat, romidepsin (FK228), panobinostat, belinostat, trichostatin A (TSA), LAQ824, or phenethyl isothiocyanate, or a salt thereof. In one embodiment, the inhibitor administered according to the provided methods is PX-12 / pleurotin, HIF-1α inhibitor (CAS number 934593-90-5), cryptotanshinone, or BAY87-2243 (1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine), or a salt thereof. In one embodiment, the inhibitor administered according to the provided methods is IDF-11774, bisphenol A / dimethylbisphenol A, or a salt thereof. Chrysin (5,7-dihydroxy-flavone), or SCH66336, or a salt thereof. In one embodiment, the inhibitor administered according to the provided methods is geldanamycin or an analog thereof, 17-AAG (Tanespimycin: allylamino-17-demethoxygeldanamycin), 17-DMAG (alvespimycin), 17AG, radicicol, KF58333, ENMD-1198, ENMD-1237, or ganetespib (ST-9090), or a salt thereof. In one embodiment, the inhibitor administered according to the provided methods prevents HIF dimerization. In one embodiment, the inhibitor administered according to the provided methods is acriflavine or a salt thereof. In one embodiment, the inhibitor administered according to the provided methods is TC-S7009, PT2385, or TAT-cyclo-CLLFVY, or a salt thereof.

[0093] In certain embodiments, the inhibitor administered in accordance with the methods provided is ganetespib or a salt thereof.

[0094] In certain embodiments, the inhibitor administered in accordance with the methods provided is BAY87-2243.

[0095] In some embodiments, the HIF1-α pathway inhibitor administered according to the provided method is a histone deacetylase inhibitor (HDACI). In one embodiment, the HDACI administered is LW6 / CAY10585 (methyl 3-(2-(4-(adamantan-1-yl)phenoxy)acetamido)-4-hydroxy-benzoate), vorinostat, romidepsin (FK228), panobinostat, belinostat, trichostatin A (TSA), LAQ824, or phenethyl isothiocyanate, or a salt thereof.

[0096] In some embodiments, the HIF1-α pathway inhibitor administered according to the provided methods is a heat shock protein inhibitor. In one embodiment, the HIF1-α pathway inhibitor administered is an HSP90 inhibitor. In one embodiment, the HSP90 inhibitor administered is geldanamycin or an analog thereof, 17-AAG (Tanespimycin: Allylamino-17-demethoxygeldanamycin), 17-DMAG (Alvespimycin), 17AG, radicicol, KF58333, ENMD-1198, ENMD-1237, or ganetespib, or a salt thereof. In certain embodiments, the heat shock protein inhibitor administered is ganetespib or a salt thereof. In one embodiment, the HIF1-α pathway inhibitor administered is an HSP70 inhibitor. In one embodiment, the HSP70 inhibitor administered is triptolide or a salt thereof.

[0097] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a HIF transactivation inhibitor. In one embodiment, the HIF1-α inhibitor administered according to the provided methods inhibits the recruitment of HIF coactivators. In one embodiment, the HIF1-α inhibitor administered is ketomin, YC-1 or KCN-1 (3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide), or a salt thereof. In another particular embodiment, the HIF1-α inhibitor administered is NSC607097 or a salt thereof. In one embodiment, the HIF1-α inhibitor administered is a proteasome inhibitor. In a further embodiment, the inhibitor administered is bortezomib or carfilzomib, or a salt thereof. In one embodiment, the HIF1-α inhibitor administered is indenopyrazole 21, FM19G11, flavopiridol, amphotericin B, actinomycin, AJM290, or AW464, or a salt thereof.In one embodiment, the HIF1-α inhibitor administered is triptolide or a salt thereof.

[0098] In certain embodiments, the HIF1-α inhibitor administered in accordance with the methods provided is YC-1, or a salt thereof.

[0099] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is an antibody or HIF1-α binding antibody fragment that binds to HIF1-α (e.g., a single chain antibody, a single domain antibody (e.g., AG1-5 VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit). In certain embodiments, the HIF1-α inhibitor administered is a VHH or a nanobody. In one embodiment, the antibody administered is AGI-5. In one embodiment, the antibody administered is AHPC.

[0100] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a HIF1 DNA binding inhibitor. In one embodiment, the HIF1-α inhibitor administered is echinomycin (NSC-13502) or the compound DJ12.162. In one embodiment, the HIF1-α inhibitor administered is an anthracycline. In a further embodiment, the inhibitor administered is doxorubicin or daunorubicin. In one embodiment, the HIF1-α inhibitor administered is a polyamide. In some embodiments, the HIF1-α inhibitor is an antibody that binds to HIF1-α, or a HIF1-α binding antibody fragment, such as a VHH or a nanobody.

[0101] In some embodiments, the HIF1-A inhibitor administered according to the provided methods is a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is an aptamer, an antisense molecule, a ribozyme, a dicer substrate, a MiRNA, a dsRNA, a ssRNA, and an shRNA. In some embodiments, the therapeutic nucleic acid is ENMD-1198 or an antisense oligonucleotide.

[0102] In some embodiments, the HIF1-A inhibitor administered according to the provided methods is an siRNA or an antisense oligonucleotide. In some embodiments, the HIF1-A inhibitor administered is ENMD-1198. In some embodiments, the HIF1-A inhibitor administered is EZN-2968.

[0103] Representative examples of human HIF1-A coding sequences are provided in GenBank Accession Nos. NM_004566.3, NM_001145443.2, NP_001138915.1, NM_001282630.2, NM_001314063.1, NM_001323016.1, NM_001323017.1, and NM_001363545.2. The sequences associated with each of these Genbank Accession Nos. are incorporated herein by reference in their entirety for all purposes. Therapeutic nucleic acids that inhibit HIF1-A activity can be routinely designed and prepared based on each of the above human HIF1-A transcript sequences using methods known in the art.

[0104] Certain embodiments of the provided methods contemplate administration of a HIF1-A inhibitory nucleic acid or any method of inhibiting gene expression of HIF1-A known in the art. Examples of inhibitory nucleic acids include, but are not limited to, antisense nucleic acids such as ENMD-1198 (small interfering RNA), small hairpin RNA (shRNA), double-stranded RNA, and any other antisense oligonucleotides. Also included are ribozymes or nucleic acids encoding any of the inhibitors described herein. The inhibitory nucleic acid may inhibit transcription of HIF1-A in cells or prevent translation of HIF1-A gene transcripts. In some embodiments, the HIF1-A inhibitory nucleic acid administered according to the provided methods is between 16 and 1000 nucleotides in length. In certain embodiments, the HIF1-A inhibitory nucleic acid administered is between 18 and 100 nucleotides in length. In certain embodiments, the HIF1-A inhibitory nucleic acid administered is at least or up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 50, 60, 70, 80, 90 nucleotides, or any range derivable therein.

[0105] In some embodiments, the HIF1-A inhibitory nucleic acid administered in accordance with the provided methods can reduce expression of HIF1-A by at least 10%, 20%, 30% or 40%, more particularly at least 50%, 60%, or 70%, and most particularly at least 75%, 80%, 90%, 95% or more, or any range or value therebetween.

[0106] In some embodiments, the HIF1-A inhibitory nucleic acid administered in accordance with the provided methods is 17-25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of mature HIF1-A mRNA (e.g., as disclosed in any one or more of GenBank Accession Nos. NM_001530.4, NM_181054.3, and NM_001243084.2). In some embodiments, the HIF1-A inhibitory nucleic acid administered is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. In some embodiments, the administered HIF1-A inhibitory nucleic acid has a sequence (5' to 3') that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary to the corresponding 5' to 3' sequence of the mature HIF1-A mRNA (e.g., as disclosed in any one or more of GenBank Accession Nos. NM_001530.4, NM_181054.3, and NM_001243084.2), or any range derivable therein. One of skill in the art would be able to use the portion of the probe sequence that is complementary to the sequence of the mature mRNA as the sequence of the mRNA inhibitor. Furthermore, that portion of the probe sequence can be modified so that it is still 90% complementary to the sequence of the mature mRNA.

[0107] In some embodiments, the HIF1-α inhibitory nucleic acid administered according to the provided methods is an miRNA mimic. In some embodiments, the HIF1-α inhibitor administered is an miR-483 mimic.

[0108] In some embodiments, the HIF1-α inhibitor administered according to the provided methods is a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is an ENMD-1198 molecule, or an antisense oligonucleotide.

[0109] Kit for administration of active agents In another embodiment, the present disclosure provides a kit comprising an HIF1-α pathway inhibitor and a PFKFB3 inhibitor, and / or other therapeutic and delivery agents. In some embodiments, a kit for preparing and / or administering the therapeutic methods described herein may be provided. The kit may comprise one or more sealed vials containing any of the pharmaceutical compositions, therapeutic agents, and / or other therapeutic and delivery agents. In some embodiments, the lipid is in one vial and the therapeutic agent is in another vial. The kit may comprise, for example, at least one inhibitor of PFKFB3 expression / activity, at least one inhibitor of HIF1-α expression / activity, and one or more reagents for preparing, formulating and / or administering the components described herein or for carrying out one or more steps of the method. In some embodiments, the kit may also comprise suitable container means, which is a container that will not react with the components of the kit, such as an Eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made of a sterilizable material, such as plastic or glass.

[0110] The kit may further comprise instructions outlining the procedural steps of the methods described herein, following substantially the same procedures as those described herein or known to those skilled in the art.For example, the kit may comprise instructions for the use of HIF1-α pathway inhibitors and PFKFB3 inhibitors, and / or other therapeutic agents, for treating neurological disorders, such as neurodegenerative disorders or neurotrauma, in a subject.The instruction information may be in a computer-readable medium that comprises machine-readable instructions that, when executed using a computer, display an actual or virtual procedure of delivering a pharmacologic amount of a therapeutic agent.

[0111] In some embodiments, kits may be provided for evaluating the expression of PFKFB3 and / or HIF-α, or related molecules. Such kits may be prepared from readily available materials and reagents. For example, such kits may include any one or more of the following substances: enzymes, reaction tubes, buffers, detergents, primers and probes, nucleic acid amplification, and / or hybridization agents. In certain embodiments, these kits allow a physician to obtain samples of blood, tears, semen, saliva, urine, tissue, serum, stool, colon, rectum, sputum, cerebrospinal fluid, and supernatants from cell lysates. In another embodiment, these kits include the equipment necessary to perform RNA extraction, RT-PCR, and gel electrophoresis. Instructions for carrying out the assay may also be included in the kit.

[0112] The kits may include components that may be individually packaged or placed in containers such as tubes, bottles, vials, syringes, or other suitable container means. The components may include probes, primers, antibodies, arrays, negative and / or positive controls. Individual components may also be provided in the kit in concentrated amounts. In some embodiments, components are provided individually at the same concentration that they would be in solution with other components. Concentrations of components may be provided as 1x, 2x, 5x, 10x, or 20x or greater.

[0113] The kit may further comprise a reagent for labeling PFKFB3 and / or HIF-1α in the sample. The kit may also comprise a labeling reagent, comprising at least one of an amine-modified nucleotide, a poly(A) polymerase, and a poly(A) polymerase buffer. The labeling reagent may comprise an amine-reactive dye or any dye known in the art.

[0114] The components of the kit may be packaged in either aqueous media or lyophilized form. The container means of the kit will generally include at least one vial, test tube, flask, bottle, syringe or other container means into which the components may be placed and preferably appropriately aliquoted. Where there are multiple components in the kit (labeling reagents and labels may be packaged together), the kit will generally also include a second, third or other additional container into which the additional components may be placed separately. However, various combinations of components may be included within a vial. The kit may also include means for containing the nucleic acid, antibody or other reagent containers in seal for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained.

[0115] When the components of the kit are provided in one and / or more solutions, the solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. Alternatively, the components of the kit may be provided as dry powder(s). When the reagents and / or components are provided as dry powders, the powder may be reconstituted by adding a suitable solvent. It is envisioned that the solvent may be provided in another container means. The container means will generally include at least one vial, test tube, flask, bottle, syringe and / or other container means into which the nucleic acid formulation may be placed, and preferably appropriately aliquoted. The kit may also include a second container means for containing a sterile pharma- ceutically acceptable buffer and / or other diluent.

[0116] The kits may also include a means for sealingly containing the vials for commercial sale, such as, for example, injection and / or blow molded plastic containers into which the desired vials are retained. The kits may also include instructions for using the components of the kit, as well as instructions for the use of other reagents not included in the kit. The instructions may include operable variations.

[0117] Method of administration Dosing regimens (e.g., dosage combined with frequency of administration) according to the methods provided herein generally include administration in an amount and frequency that provides a desired effect, e.g., administration of an amount effective to provide improvement of one or more symptoms of a neurological disorder in a subject, such as a neurodegenerative disorder, such as PD or AD, or one or more symptoms associated with neurotrauma. Administration of the compositions is typically via any common route, including, but not limited to, oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous injection. Oral formulations include commonly used excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and contain about 10% to about 95%, or about 25% to about 70% of the active ingredient. Typically, the compositions are administered in a manner compatible with the dosage form, and in a therapeutically effective amount. The amount administered depends on the subject being treated. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner.

[0118] In some embodiments, the composition is administered parenterally. As used herein, the phrases "parenteral administration" and "parenterally administered" refer to modes of administration other than enteral and topical administration, such as by injection, including, but not limited to, intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intrarenal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0119] In certain embodiments, the compositions provided herein are administered to contact neural cells or tissues, such as central nervous system (CNS) cells or tissues. Such tissues include brain and spinal cord (e.g., cervical, thoracic, or lumbar) tissues. Thus, in some embodiments, the compositions provided herein are administered to treat neural cells / tissues in vivo via direct intracranial injection or injection into the cerebrospinal fluid. Alternatively, the compounds provided herein can be administered systemically (e.g., intravenously) and contact the affected neural tissue through other mechanisms, such as lesions (if the blood-brain barrier is compromised). In some embodiments, the compositions administered are in a form that can cross the blood-brain barrier and enter the nervous system (e.g., CNS). In further embodiments, the compositions administered are formulated for such administration to neural tissues.

[0120] The preparation for parenteral administration is preferably a sterile aqueous preparation of active agent, and this preparation is preferably isotonic with the blood of intended recipient.These preparations can be administered by subcutaneous, intravenous, intramuscular or intradermal injection.This preparation can be conveniently prepared by mixing compound with water or glycine buffer, and making the resulting solution sterile and isotonic with blood.

[0121] In some embodiments, the composition is administered orally. Formulations suitable for oral administration may be presented as separate units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of active ingredient; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions. Such formulations can be prepared by any suitable method of pharmacy, including combining the active compound with a suitable carrier, which may contain one or more accessory ingredients as described above. In general, the formulations provided are prepared by uniformly and thoroughly mixing the active compound with a liquid carrier or finely divided solid carrier or both, and then, if necessary, shaping the resulting mixture. For example, tablets can be prepared by compressing or molding a powder or granules containing the active agent, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing the compound in free-flowing form as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, and / or surface active / dispersing agent(s), in a suitable machine. Molded tablets may be made by molding in a suitable machine the powdered compound moistened with an inert liquid binder.

[0122] Formulations suitable for buccal (sublingual) administration include lozenges, which usually contain the active agent in a flavored base such as sucrose and acacia or tragacanth; and pastilles, which contain the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia.

[0123] Formulations suitable for topical application (e.g., in the mouth, nasopharynx, or oropharynx) take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers that can be used include petrolatum, lanolin, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more of these.

[0124] In some embodiments, the present disclosure provides methods of treatment in which the compositions provided herein are administered in combination with one or more additional therapeutic agents (e.g., therapeutic agents used to prevent and / or treat neurological diseases and / or conditions, or the effects associated therewith (e.g., pain). The combination of the compositions provided and the therapeutic agent(s) can be administered in any conventional dosage form or co-administered (e.g., sequentially, simultaneously, at different times). Co-administration herein refers to administering more than one therapeutic agent to a subject in the course of coordinated treatment to achieve an improved clinical outcome. Such co-administration can be coextensive, i.e., during overlapping periods of time. For example, a first therapeutic agent can be administered to a patient before, simultaneously with, before, after, or after administration of a second active agent. In some embodiments, the therapeutic agents are combined / formulated in a single composition and thus administered to a subject simultaneously.

[0125] Treatment and Methods of Use Neurological disorders The methods and compositions provided are used in treating neurological disorders. In one embodiment, the disclosure provides a method of treating a neurological disorder in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method provides said wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0126] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0127] In some embodiments, the neurological disease treated in accordance with the provided methods is mild cognitive impairment (MCI), age-associated memory impairment (AAMI), neuropathy, neurodegenerative disease, seizure-related injury, multiple sclerosis, amyotrophic lateral sclerosis, stroke-related injury, cerebral aneurysm-related injury, spinal cord injury (e.g., contusion, compression or laceration), concussion-related injury (including post-concussion syndrome), cerebral ischemia, or injury resulting from or related to traumatic brain injury.

[0128] In some embodiments, the neurological disease treated in accordance with the methods provided is mild cognitive impairment (MCI) or age-associated memory impairment (AAMI).

[0129] In some embodiments, the neurological condition treated in accordance with the methods provided is a neuropathy.

[0130] In some embodiments, the neurological disease treated according to the provided method is a neurodegenerative disease. In some embodiments, the neurodegenerative disease treated is Alzheimer's disease (AD), Parkinson's disease (PD), or Huntington's disease (HD). In certain embodiments, the neurodegenerative disease treated is AD. In certain embodiments, the neurodegenerative disease treated is PD. In certain embodiments, the neurodegenerative disease treated is HD.

[0131] In some embodiments, the neurodegenerative disease treated in accordance with the methods provided is selected from amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, and frontotemporal lobar degeneration.

[0132] In some embodiments, the neurological disease treated in accordance with the provided methods is dementia (e.g., senile dementia of the AD type (SDAT), vascular dementia, or dementia with Lewy bodies).

[0133] In some embodiments, the neurological disease treated according to the provided methods is neurotrauma. In some embodiments, the neurotrauma is an injury to the central nervous system (CNS). In one embodiment, the injury to the CNS is a spinal cord injury (SCI). In a further embodiment, the SCI is an acute SCI. In one embodiment, the injury to the CNS is a traumatic brain injury. In one embodiment, the CNS injury treated according to the provided methods is cerebral ischemia.

[0134] In some embodiments, the subject treated according to the methods provided is at risk for suffering from a neurological disease, hi some embodiments, the methods provided are performed as a prophylactic treatment for a neurological condition.

[0135] In some embodiments, the methods and compositions provided prevent neurological disease in a subject at risk of developing a neurological disease, e.g., a subject having one or more risk factors associated with developing a neurological disease. In some embodiments, the subject has one or more risk factors selected from age 55 or older, smoking, obesity, diabetes, metabolic syndrome, heart disease, high blood pressure, stroke, myocardial infarction, family history of neurological disease, exposure to solvents, exposure to pesticides, head injury, or brain trauma.

[0136] In some embodiments, the subject treated according to the method provided suffers from or has been diagnosed as suffering from a neurological disease.The onset of a neurological disease, such as a neurodegenerative disease, can be routinely detected and evaluated using standard clinical techniques known in the art, such as cognitive tests, functional tests including behavioral reflex tests; balance, coordination and gait tests, and deep tendon reflex tests; qualitative tests of mental status, cranial nerves, motor system, and sensory system; biochemical assays; nerve and muscle biopsies; and computer axial tomography (CAT) scan, computer tomography (CT), magnetic resonance imaging (MRI), transcranial Doppler, neurosonography, electroencephalogram (EEG), SPECT scan, positive electric subemission computed tomography (PET), or diffusion weighted imaging (DWI).

[0137] In some embodiments, the present disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of a neurological disease by administering a composition provided herein to a subject prior to the onset of a neurological disease, e.g., prior to the onset of one or more symptoms of a neurological disease. In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of a neurological disease. In some embodiments, treating a neurological disease according to the methods provided herein includes delaying the onset of one or more symptoms of a neurological disease.

[0138] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of a neurological disease. In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered to inhibit the progression of a neurological disease. In some embodiments, the methods and compositions provided are used to treat one or more different stages of a neurological disease.

[0139] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0140] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0141] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0142] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0143] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0144] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0145] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0146] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0147] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0148] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0149] In some embodiments, the methods provided herein for treating a neurological disease are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0150] In some embodiments, the HIF1-α pathway inhibitor and / or PFKFB3 inhibitor is administered orally. In some embodiments, the HIF1-α pathway inhibitor and / or PFKFB3 inhibitor is administered transmucosally, as a syrup, topically, parenterally, by injection, subcutaneously, rectally, bucally, or transdermally.

[0151] In some embodiments, treating a neurological disease according to the methods provided herein includes alleviating one or more symptoms of the neurological disease in a subject, compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the alleviated one or more symptoms of the neurological disease are selected from forgetfulness, cognitive impairment, personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerky movements and tremors, dementia, slurred speech, drooling, impaired judgment, difficulty swallowing, muscle stiffness, impaired posture and balance; loss of automatic movements, difficulty writing, reduced apoptosis / destruction / loss of number and / or function of nerve cells and / or tissues; increased survival of nerve cells and / or tissues (e.g., neurons); reduced or delayed neurodegeneration; restoration of motor function; reduced long-term damage to nerve cells / tissues and / or surrounding cells / tissues; reduced inflammation of nerve cells / tissues; reduced oxidative stress of nerve cells / tissues; improved behavioral reflexes, and increased survival / survival. In some embodiments, one or more symptoms of the neurological disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject prior to treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[0152] Neurological tests for identifying and monitoring neurological diseases are known in the art. Diagnosis, treatment, prevention, and progression of neurological diseases can be routinely evaluated using various techniques known in the art. In some embodiments, the treatment of neurological diseases includes reducing or eliminating one or more of the above symptoms. In some embodiments, the treatment includes reducing or eliminating one or more of apoptosis, inflammation, and / or ischemia-reperfusion injury of neural cells or neural tissue in a subject in need of treatment. In some embodiments, the treatment includes reducing or eliminating cognitive impairment, motor impairment, and / or sensory impairment in a subject in need of treatment.

[0153] As used herein, the term "neurological examination" refers to any test, currently known or unknown, that is useful for identifying and / or measuring neurological activity, including anatomical examinations, functional tests, and biochemical assays. Examples of neurological examinations include, but are not limited to, CAT scans, magnetic resonance imaging (MRI), transcranial Doppler, neurosonography, electroencephalography (EEG), SPECT scans, computed tomography (CT), positive electric subemission computed tomography (PET), diffusion weighted imaging (DWI), and more qualitative tests of mental status, cranial nerves, motor system, sensory system, deep tendon reflexes, coordination, and gait.

[0154] In some embodiments, treating a neurological disease according to the methods provided herein reduces one or more cognitive, behavioral, and / or physical impairments in a subject. In some embodiments, treating a neurological disease according to the methods provided herein includes increasing or improving one or more neurological parameters in a subject compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the one or more improved neurological parameters are selected from impaired cognition and / or memory; impaired balance, coordination, and / or walking; impaired reflexes; tremors, twitching, and / or jerky movements; mood swings; dementia; impaired speech and / or writing; and neuronal loss. Each of these neurological parameters can be routinely monitored using techniques described herein or known in the art.

[0155] In some embodiments, administration of the provided compositions has use in (i) improving cognition, and / or (ii) treating and / or preventing cognitive disorders. In some embodiments, administration of the provided compositions has use in (i) improving cognition, and / or (ii) treating and / or preventing cognitive dysfunction in a subject. Cognitive function in a human subject can be routinely determined using methods known in the art, including, for example, the RAVLT cognitive test, the Repeatable Battery for the Assessment of Neuropsychological Status, or the California Verbal Learning Test. In some embodiments, the subject's cognition is assessed using the Wechsler Memory Scale [WMS]-Verbal Paired Association (VPA) test, the Rey Auditory Verbal Learning Test Recall [RAVLT Recall], cognitive tests, the WMS Digit Spanning Test, the Controlled Word Association Test [COWAT], the Semantic Fluency Test, the Trail Making Test [TMT], the Orientation Task, the ADAS-cog test, or the Letter-Digit Substitution Test.

[0156] In some embodiments, the provided method prevents, reduces, or delays neurological disease. In some embodiments, the provided method is administered to a subject at risk of developing neurological disease. In such a subject, the prevention of neurological disease can be monitored by the absence of typical features of neurological disease. For example, a subject prophylactically administered an effective amount of a HIF1-α inhibitor and an effective amount of a PFKFB3 inhibitor may not experience or experience a reduced incidence of one or more of the following symptoms: cognitive and / or memory impairment; balance, coordination, and / or gait impairment; reflex impairment; tremors, twitching, and / or jerky movements; mood swings; dementia; speech and / or writing impairment; and neuronal cell loss.

[0157] In additional embodiments, the methods provided include further administering an additional therapeutic agent to the subject.

[0158] Neurodegenerative diseases Neurodegenerative diseases are disorders of the central nervous system characterized by a progressive, usually gradual, loss of functional neural tissue. Neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and Huntington's disease, affect millions of people worldwide. Currently, in the United States alone, nearly one million people live with Parkinson's disease. There is currently no known cure, but treatment options, including surgery and medications, are available to manage the symptoms.

[0159] In one embodiment, the present disclosure provides a method of treating a neurodegenerative disease in a subject in need thereof, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The method provides said wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0160] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0161] In some embodiments, the neurodegenerative disease treated in accordance with the provided methods is Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, frontotemporal lobar degeneration, Creutzfeldt-Jakob disease, or dementia.

[0162] In some embodiments, the neurodegenerative disease treated according to the provided methods is Alzheimer's disease (AD), Parkinson's disease (PD), or Huntington's disease (HD). In certain embodiments, the neurodegenerative disease treated is AD. In certain embodiments, the neurodegenerative disease treated is PD. In certain embodiments, the neurodegenerative disease treated is HD.

[0163] In some embodiments, the neurodegenerative disease treated according to the methods provided is selected from amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, and frontotemporal lobar degeneration. In certain embodiments, the neurodegenerative disease treated is ALS.

[0164] In some embodiments, the neurodegenerative disease treated according to the methods provided is dementia. In further embodiments, the dementia treated is senile dementia of the AD type (SDAT), vascular dementia, dementia with Lewy bodies, or dementia pugilistica.

[0165] In some embodiments, the subject treated according to the methods provided is at risk for developing a neurodegenerative disease, hi some embodiments, the methods provided are performed as a prophylactic treatment for a neurodegenerative disease.

[0166] In some embodiments, the provided method prevents neurodegenerative disease in a subject at risk of developing neurodegenerative disease, for example, a subject having one or more risk factors associated with the development of neurodegenerative disease.In some embodiments, the subject has one or more risk factors selected from age 55 or older, smoking, obesity, diabetes, heart disease, high blood pressure, stroke, myocardial infarction, family history of neurodegenerative disease, metabolic syndrome, exposure to solvents, exposure to pesticides, head injury or brain trauma.

[0167] In some embodiments, the subject treated according to the provided method suffers from or has been diagnosed as suffering from a neurodegenerative disease.The onset of a neurodegenerative disease can be routinely detected and evaluated using standard clinical techniques known in the art, such as cognitive tests, functional tests including behavioral reflex tests; balance, coordination and gait tests, and deep tendon reflex tests; qualitative tests of mental status, cranial nerves, motor system, and sensory system; biochemical assays; nerve and muscle biopsies; and computer axial tomography (CAT) scan, computer tomography (CT), magnetic resonance imaging (MRI), transcranial Doppler, neurosonography, electroencephalogram (EEG), SPECT scan, positive electric subemission computed tomography (PET), or diffusion weighted imaging (DWI).

[0168] In some embodiments, the present disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of a neurodegenerative disease by administering a composition provided herein to a subject prior to the onset of the neurodegenerative disease, e.g., prior to the onset of one or more symptoms of the neurodegenerative disease. In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of the neurodegenerative disease. In some embodiments, treating a neurodegenerative disease according to the methods provided herein includes delaying the onset of one or more symptoms of the neurodegenerative disease.

[0169] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of a neurodegenerative disease. In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered to inhibit the progression of a neurodegenerative disease. In some embodiments, the methods and compositions provided are used to treat one or more different stages of a neurodegenerative disease.

[0170] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0171] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0172] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0173] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0174] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0175] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0176] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0177] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0178] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0179] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0180] In some embodiments, the methods provided herein for treating a neurodegenerative disease are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0181] In some embodiments, the HIF1-α pathway inhibitor and / or PFKFB3 inhibitor is administered orally. In some embodiments, the HIF1-α pathway inhibitor and / or PFKFB3 inhibitor is administered transmucosally, as a syrup, topically, parenterally, by injection, subcutaneously, rectally, bucally, or transdermally.

[0182] In some embodiments, treating a neurodegenerative disease in accordance with the methods provided herein comprises alleviating one or more symptoms of the neurodegenerative disease in a subject compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0183] In some embodiments, the one or more symptoms of the neurodegenerative disease that are alleviated are selected from forgetfulness, cognitive impairment, personality changes, depression, mood swings, unsteady gait, twitching and jerky movements and tremors, dementia, slurred speech, drooling, impaired judgment, difficulty swallowing, muscle rigidity, impaired posture and balance; loss of automatic movements, difficulty writing, reduced apoptosis / destruction / loss of number and / or function of nerve cells and / or tissues; increased survival of nerve cells and / or tissues (e.g., neurons); reduced or delayed neurodegeneration; restoration of motor function; reduced long-term damage to nerve cells / tissues and / or surrounding cells / tissues; reduced inflammation of nerve cells / tissues; reduced oxidative stress of nerve cells / tissues; improved behavioral reflexes, and increased survival / survival. In some embodiments, the one or more symptoms of the neurodegenerative disease are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject before treatment with the HIF1-α pathway inhibitor and the PFKFB3 inhibitor.

[0184] Treatment and / or prevention of neurodegenerative disease can be measured by various means routinely used in the art. In some embodiments, treatment comprises reducing or eliminating one or more of the above symptoms. In some embodiments, treatment comprises reducing or eliminating one or more of apoptosis or inflammation of nerve cells or tissue, or reducing or eliminating cognitive impairment, motor impairment and / or sensory impairment in a subject suffering from neurodegenerative disease.

[0185] Neurological tests for identifying and monitoring neurodegenerative diseases are known in the art. As used herein, the term "neurological test" refers to any test, currently known or unknown, that is useful for identifying and / or measuring neurological activity, including anatomical tests, functional tests, and biochemical assays. Examples of neurological tests include, but are not limited to, CAT scan, magnetic resonance imaging (MRI), transcranial Doppler, neurosonography, electroencephalography (EEG), SPECT scan, computed tomography (CT), positive electric subemission computed tomography (PET), diffusion weighted imaging (DWI), and more qualitative tests of mental status, cranial nerves, motor system, sensory system, deep tendon reflexes, coordination, and gait.

[0186] In some embodiments, treating a neurodegenerative disease according to the methods provided herein reduces one or more cognitive, behavioral, and / or physical impairments in a subject. In some embodiments, treating a neurodegenerative disease according to the methods provided herein includes increasing or improving one or more neurological parameters in a subject compared to the subject's parameters before treating with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the one or more improved neurological parameters are selected from cognitive and / or memory impairment; balance, coordination, and / or gait impairment; reflex impairment; tremors, twitching, and / or jerky movements; mood swings; dementia; speech and / or writing impairment; and neuronal loss. These parameters can be monitored by routine techniques described herein or known in the art.

[0187] In some embodiments, administration of the provided compositions has use in (i) improving cognition, and / or (ii) treating and / or preventing cognitive disorders. In some embodiments, administration of the provided compositions has use in (i) improving cognition, and / or (ii) treating and / or preventing cognitive dysfunction in a subject. Cognitive function in a human subject can be routinely determined using methods known in the art, including, for example, the RAVLT cognitive test, the Repeatable Battery for the Assessment of Neuropsychological Status, or the California Verbal Learning Test. In some embodiments, the subject's cognition is assessed using the Wechsler Memory Scale [WMS]-Verbal Paired Association (VPA) test, the Rey Auditory Verbal Learning Test Recall [RAVLT Recall], cognitive tests, the WMS Digit Spanning Test, the Controlled Word Association Test [COWAT], the Semantic Fluency Test, the Trail Making Test [TMT], the Orientation Task, the ADAS-cog test, or the Letter-Digit Substitution Test.

[0188] In some embodiments, the provided method prevents, reduces or delays neurodegenerative disease. The method can be administered to patients who are at risk of developing neurodegenerative disease. In such subjects, the prevention of neurodegenerative disease can be monitored by the absence of typical features of neurodegenerative disease. For example, the subject prophylactically administered with an effective amount of HIF1-α inhibitor and an effective amount of PFKFB3 inhibitor may not experience or experience a reduced incidence of one or more of the following symptoms: cognitive and / or memory impairment; balance, coordination and / or gait impairment; reflex impairment; tremors, twitching and / or jerky movements; mood swings; dementia; speech and / or writing impairment; and neuronal cell loss.

[0189] In additional embodiments, the methods provided include further administering an additional therapeutic agent to the subject.

[0190] Alzheimer's Disease Alzheimer's disease (AD) is an age-related neurodegenerative disease, and is currently the most common cause of dementia. Clinically, AD is characterized by a progressive decline in cognitive function, with memory deficits, together with speech impairment (language impairment with impairment in any understanding of speech), dyspraxia (impaired ability to coordinate and execute specific purposeful movements and gestures despite the absence of motor or sensory impairment), and cognitive impairment (ability to recognize objects, people, sounds, shapes, or smells) due to the involvement of the cortical association areas of the brain. Exemplary clinical symptoms of AD include mild forgetfulness, difficulty solving simple math problems, difficulty remembering how to do simple tasks, inability to think clearly; difficulty speaking, understanding, reading, or writing; confusion, irritability, mood swings, anxiety, aggression, or tendency to wander from home.

[0191] In some embodiments, the present disclosure provides methods and compositions for treating Alzheimer's disease (AD) in a subject, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The methods and compositions provide wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0192] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0193] In some embodiments, the subject is at risk of developing AD. In some embodiments, the methods provided herein (e.g., any of (a)-(c) above) are performed as a preventative treatment for AD.

[0194] In some embodiments, the methods and compositions provided prevent AD in a subject at risk of developing AD, e.g., a subject having one or more risk factors associated with developing AD. In some embodiments, the subject has one or more risk factors selected from age 65 or older, smoking, alcohol, a family history of AD, head injury or traumatic brain injury, diabetes, and heart disease.

[0195] In some embodiments, the subject suffers from AD. In some embodiments, the subject has been diagnosed with AD. AD can be diagnosed by a physician using any technique known in the art, including, for example, medical history, mental status examination, physical and neurological examination, diagnostic tests, and brain imaging to diagnose AD.

[0196] In some embodiments, the present disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of AD by administering to a subject prior to the onset of AD, e.g., prior to the onset of one or more symptoms of AD. Among the most consistent risk factors for AD are age, sex, ethnicity, and family history of AD.

[0197] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of AD. In some embodiments, the subject exhibits at least one of the following: memory loss interfering with daily life, difficulty planning or solving problems, difficulty completing familiar tasks, confusion about time or place, difficulty understanding visual images and spatial relationships, new problems with words in speaking or writing, misplacing objects and loss of ability to backtrack, impaired or poor judgment, withdrawal from work or social activities, or changes in mood and personality. In some embodiments, the provided methods and compositions may reduce the incidence, severity, or level of memory impairment, confusion, and difficulty speaking and / or problem solving. In some embodiments, the provided methods and compositions improve the cognitive status of the subject as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, treating AD according to the methods provided herein includes delaying the onset of one or more symptoms of AD.

[0198] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of AD. In some embodiments, the methods and compositions provided can be used to treat different stages of AD.

[0199] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0200] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0201] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0202] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0203] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0204] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0205] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0206] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0207]

[0208] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0209] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0210] In some embodiments, the methods provided herein for treating AD are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0211] In some embodiments, treating AD according to the methods provided herein includes alleviating one or more symptoms of AD in a subject compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the alleviated one or more symptoms of AD are selected from memory loss that interferes with daily life, difficulty planning or solving problems, difficulty completing familiar tasks, confusion about time or place, difficulty understanding visual images and spatial relationships, new problems with words in speaking or writing, misplacing objects and losing the ability to backtrack, impaired or poor judgment, withdrawal from work or social activities, or changes in mood and personality. In some embodiments, treating AD according to the methods provided herein is indicated by an improvement in mental cognitive status, for example, as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, improvement in psychocognitive status is indicated by an improvement in the psychocognitive status test score of at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject's cognitive score in a corresponding test prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0212] Treatment of AD can be measured by various means using techniques known in the art.In some embodiments, treatment comprises reducing one or more of the following AD symptoms in subject: forgetfulness, difficulty in solving simple math problems, difficulty in remembering how to do simple tasks, inability to think clearly; difficulty in speaking, understanding, reading or writing; confusion, irritability, mood swings, anxiety, aggression or tendency to wander away from home.

[0213] In some embodiments, treating AD in accordance with the methods provided herein comprises increasing one or more parameters selected from maintaining / improving quality of life, maximizing function in daily activities, enhancing cognition, improving a subject's mood, and improving a subject's behavior.

[0214] In some embodiments, the method provided prevents AD. The method can be administered to patients who are at risk of developing AD. In such subjects, the prevention of AD can be monitored by the absence of typical features of AD. For example, the subject who is prophylactically administered an effective amount of a HIF1-α inhibitor and an effective amount of a PFKFB3 inhibitor may not experience or experience a reduced incidence of one or more of the following symptoms: memory loss that interferes with daily life, difficulty planning or solving problems, difficulty completing familiar tasks, confusion about time or place, difficulty understanding visual images and spatial relationships, new problems with words in speaking or writing, misplacing objects and losing the ability to backtrack, impaired or poor judgment, withdrawal from work or social activities, or changes in mood and personality.

[0215] In some embodiments, the provided methods delay the onset of AD. Thus, the provided methods delay the average onset of AD by more than 5 years, more than 10 years, more than 11 years, more than 12 years, more than 13 years, more than 14 years, more than 15 years, more than 16 years, more than 17 years, more than 18 years, more than 19 years, or more than 20 years from the first diabetes diagnosis.

[0216] In some embodiments, the methods provided reduce, alleviate, reduce the severity, or reverse one or more symptoms of AD. In some embodiments, the methods of treating AD with anti-HIF1-α and / or anti-PFKFB3 antibodies or antigen-binding fragments thereof may reduce, alleviate, reduce the severity, or reverse one or more of the following symptoms of AD: memory loss interfering with daily life, difficulty planning or solving problems, difficulty completing familiar tasks, confusion about time or place, difficulty understanding visual images and spatial relationships, new problems with words in speaking or writing, misplacing objects and loss of ability to backtrack, impaired or poor judgment, withdrawal from work or social activities, or changes in mood and personality.

[0217] In additional embodiments, the methods provided include further administering an additional therapeutic agent to the subject. In one embodiment, the additional therapeutic agent is an acetylcholinesterase inhibitor. In one embodiment, the additional therapeutic agent is an NMDA receptor antagonist. In another embodiment, the additional therapeutic agent is memantine.

[0218] Parkinson's disease Parkinson's disease (PD) is a degenerative disorder of the central nervous system caused by the death of dopamine-producing (DA) neurons in the substantia nigra, a region of the midbrain. PD affects nearly 1 million Americans, with 50,000 new cases diagnosed in the United States each year. PD is the second most common neurodegenerative disease after Alzheimer's disease. The prevalence of PD is approximately 0.3% of the total population in developed countries. Genetically related familial PD has an early onset (between ages 20 and 50), whereas the more common sporadic PD occurs after age 50 (mean age 57 ± 11 years).

[0219] The main motor symptoms of PD are collectively referred to as parkinsonism, or "parkinsonism." Early in the course of PD, the most obvious symptoms are movement-related, including tremor, rigidity, postural instability, slowness of movement, difficulty walking, gait disturbance, and tendency to fall. Later, cognitive and behavioral problems may develop, and dementia commonly occurs in advanced stages of the disease.

[0220] In some embodiments, the disclosure provides methods and compositions for treating PD in a subject, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The methods and compositions provide wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0221] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0222] In some embodiments, the subject is at risk of developing PD. In some embodiments, the methods provided herein (e.g., any of (a)-(c) above) are performed as a preventative treatment for PD.

[0223] In some embodiments, the methods and compositions provided prevent PD in a subject at risk of developing PD, e.g., a subject having one or more risk factors associated with developing PD, hi some embodiments, the subject is male, aged 60 years or older, and / or has been continuously exposed to herbicides or pesticides.

[0224] In some embodiments, the disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of PD by administration to a subject prior to the onset of PD, e.g., prior to the onset of one or more symptoms of PD.

[0225] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered before the onset of one or more symptoms of PD. In some embodiments, the provided method prevents PD. The method can be administered to a patient at risk of developing PD. In such a subject, the prevention of PD can be monitored by the absence of typical characteristics of PD. For example, a subject to which an effective amount of a HIF1-α inhibitor and a PFKFB3 inhibitor is administered prophylactically may not experience or may experience a reduced incidence of one or more of the following symptoms: tremor (or shaking of, for example, limbs, often hands and fingers), slowness of movement (bradykinesia), muscle stiffness, impaired posture and balance, loss of automatic movements, changes in speech, or difficulty in writing.

[0226] In some embodiments, the subject has been diagnosed with PD. Currently, there is no single test or scan for Parkinson's disease, but bradykinesia (slowness of movement) and tremors or rigidity are telltale symptoms that help doctors make a diagnosis.

[0227] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of PD. There are five stages in the progression of PD. In some embodiments, the methods and compositions provided can be used to treat different stages of PD.

[0228] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0229] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0230] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0231] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0232] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0233] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0234] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0235] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0236] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0237] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0238] In some embodiments, the methods provided herein for treating PD are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0239] In some embodiments, treating PD according to the methods provided herein includes reducing one or more symptoms of PD in a subject compared to the subject prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the one or more reduced symptoms of PD are selected from tremors (or shaking of limbs, often hands and fingers, for example), slowness of movement (bradykinesia), muscle rigidity, impaired posture and balance, loss of automatic movements, changes in speech, and difficulty with writing. In some embodiments, treating PD according to the methods provided herein is indicated by an improvement in a psychocognitive status, for example, as measured using a psychocognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, one or more symptoms of PD. In some embodiments, the improvement in a psychocognitive status is indicated by an improvement in a psychocognitive status test score of at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to the subject's cognitive score on a corresponding test prior to treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0240] Treatment of PD can be measured by a variety of means using techniques known in the art. In some embodiments, treatment includes reducing one or more of the following PD symptoms in a subject: tremors (or shaking, e.g., of the limbs, often the hands and fingers), slowness of movement (bradykinesia), muscle stiffness, impaired posture and balance, loss of automatic movements, changes in speech, and difficulty with writing.

[0241] In some embodiments, treating PD in accordance with the methods provided herein comprises increasing / improving one or more parameters selected from reducing muscle stiffness, improving walking ability, reducing involuntary movements, reducing fatigue, reducing dizziness, improving sleep, maintaining / improving quality of life, maximizing function in daily activities, enhancing cognition, improving a subject's mood, and improving a subject's behavior.

[0242] In additional embodiments, provided methods include further administering an additional therapeutic agent to the subject. In one embodiment, the additional therapeutic agent is a dopamine agonist. In a further embodiment, the additional therapeutic agent is levodopa.

[0243] Huntington's disease Huntington's disease (HD) is a severe, progressive, inherited neurodegenerative disorder with symptoms that may include chorea, rigidity, writhing movements, physical instability; difficulty chewing, swallowing, and speaking; sleep disorders, cognitive impairment, memory deficits, anxiety, depression, aggression, and obsessive-compulsive behavior. The physical symptoms of Huntington's disease usually develop between the ages of 35 and 44. Life expectancy is approximately 20 years after onset of physical symptoms.

[0244] In some embodiments, the disclosure provides methods and compositions for treating Huntington's disease (HD) in a subject, comprising: (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The methods and compositions provide wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0245] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0246] In some embodiments, the subject is at risk of developing HD. In some embodiments, the methods provided herein (e.g., any of (a)-(c) above) are performed as a prophylactic treatment for HD.

[0247] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered prior to the onset of one or more symptoms of HD. In some embodiments, the disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of HD by administering to a subject prior to the onset of HD, e.g., prior to the onset of one or more symptoms of HD.

[0248] In some embodiments, the methods and compositions provided prevent HD in a subject at risk of developing HD, e.g., a subject having one or more risk factors associated with developing HD. In some embodiments, the subject has a family history of HD or a mutation in the HTT gene (e.g., a CAG repeat mutation).

[0249] In some embodiments, the subject has been diagnosed with HD or with PD. A preliminary HD diagnosis is usually made by a general physical examination, review of family medical history, and neurological and / or psychiatric examinations.

[0250] In some embodiments, the disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of HD by administering a composition provided herein to a subject prior to the onset of HD, e.g., prior to the onset of one or more symptoms of HD. In some embodiments, treating HD according to the methods provided herein includes delaying the onset of one or more symptoms of HD.

[0251] In some embodiments, the provided method prevents HD. The method can be administered to patients who are at risk of developing HD. In such subjects, the prevention of HD can be monitored by the absence of typical characteristics of HD. For example, the subject who is prophylactically administered an effective amount of HIF1-α inhibitor and an effective amount of PFKFB3 inhibitor may not experience or experience a reduced incidence of one or more of the following symptoms: personality change, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerking movements and tremors, dementia, slurred speech, impaired judgment, difficulty swallowing, and drunken appearance.

[0252] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of HD.

[0253] In some embodiments, the provided methods and compositions can be used to treat different stages of HD. Symptoms of Huntington's disease usually appear between about 30-50 years of age, and the disease usually progresses over a period of 10-25 years. Characteristics and symptoms of the disease include personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerky movements and tremors, dementia, slurred speech, impaired judgment, difficulty swallowing, and a drunken appearance. Once symptoms of Huntington's disease appear, the course of the disease is roughly divided into three stages (early, middle, and late), lasting a total of 10-30 years. In the early stages of HD, patients are able to perform most of their usual activities, involuntary movements are generally mild, speech is usually clear, and dementia, if any, is mild. In the early stages, patients may exhibit slightly uncontrollable movements, stumbling and clumsiness, lack of concentration, poor short-term memory and depression, and mood swings.

[0254] In the intermediate stage of HD, patients become more disabled and usually require assistance with some of the normal activities of daily living. Falls, weight loss and swallowing problems can become problems during the intermediate stage of HD, and dementia and uncontrolled movements become more prominent.

[0255] In the later stages of HD, patients deteriorate to the point where they require almost complete care: they may no longer be able to walk or talk, their involuntary movements become more rigid, and they are often unaware of their surroundings or unable to swallow food.

[0256] In some embodiments, the provided methods are administered to a subject during the early stages of HD. In some embodiments, the provided methods are administered to a subject during the middle stages of HD. In some embodiments, the provided methods are administered to a subject during the late stages of HD.

[0257] In some embodiments, a subject treated according to the methods provided herein exhibits at least one of the following symptoms of HD: difficulty concentrating, memory lapses, depression, stumbling and clumsiness, or mood swings such as irritability and aggressive behavior. In some embodiments, the methods and compositions provided may reduce the incidence, severity, or level of memory impairment, confusion, and difficulty speaking and / or problem solving. In some embodiments, the methods and compositions provided improve the cognitive status of the subject, as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, treating HD according to the methods provided herein includes delaying the onset of one or more symptoms of HD.

[0258] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0259] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0260] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0261] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0262] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0263] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0264] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0265] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0266] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0267] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0268] In some embodiments, the methods provided herein for treating HD are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0269] In some embodiments, treating HD according to the methods provided herein includes reducing one or more symptoms of HD in a subject, compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the reduced one or more symptoms of HD are selected from personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerky movements and tremors, dementia, slurred speech, impaired judgment, difficulty swallowing, and drunken appearance. In some embodiments, treating HD according to the methods provided herein is indicated by an improvement in mental cognitive status, for example, as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, one or more symptoms of HD. In some embodiments, the improvement in mental cognitive status is indicated by an improvement in the mental cognitive status test score of at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, compared to the subject's cognitive score in the corresponding test before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0270] Treatment of HD can be measured by a variety of means using techniques known in the art. In some embodiments, treatment includes reducing one or more of the following symptoms of HD in a subject: personality changes, depression, mood swings, unsteady gait, involuntary chorea, twitching and jerky movements and tremors, dementia, slurred speech, impaired judgment, difficulty swallowing, and an intoxicated appearance.

[0271] In some embodiments, treating HD in accordance with the methods provided herein comprises increasing one or more parameters selected from maintaining / improving quality of life, maximizing function in daily activities, enhancing cognition, improving a subject's mood, and improving a subject's behavior.

[0272] In additional embodiments, the methods provided include further administering to the subject an additional therapeutic agent, hi one embodiment, the additionally administered therapeutic agent is tetrabenazine.

[0273] Neurotrauma In some embodiments, the present disclosure provides methods and compositions for treating neurotrauma (e.g., traumatic brain injury, stroke, cerebral or spinal hemorrhage, cerebral infarction, and spinal cord injury). In some embodiments, the present disclosure provides methods and compositions for treating neurotrauma (NT) in a subject in need thereof, (a) administering to a subject an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The methods and compositions provide wherein the PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α.

[0274] In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a HIF1-α pathway inhibitor and the subject has previously been administered a PFKFB3 inhibitor. In one embodiment, the subject is administered an effective amount of a PFKFB3 inhibitor and the subject has previously been administered a HIF1-α pathway inhibitor.

[0275] In some embodiments, the subject is at risk of suffering from NT. In some embodiments, the methods provided herein (e.g., any of (a)-(c) above) are performed as a prophylactic treatment of NT. In some embodiments, the methods and compositions provided prevent NT in a subject at risk of developing NT. Subjects at risk of trauma include those about to undergo surgery, those involved in combat (e.g., military combat), contact sports (e.g., rugby, soccer, boxing, and mixed martial arts), and accidents (e.g., automobile accidents).

[0276] In some embodiments, the subject has or has been diagnosed with NT. NT can be diagnosed by a physician using any technique known in the art, including, for example, biomarker testing, clinical response testing, computed tomography (CT), and magnetic resonance imaging (MRI).

[0277] A patient may be suspected of having NT injury, for example, after a physician's examination, based on neurological symptoms (motor, sensory, cognitive) consistent with NT and / or radiological evaluation (MRI, CT scan, X-ray). In some embodiments, a patient suspected of having NT, particularly a spinal cord injury, may have a rating of A or B on the American Spinal Cord Injury Association (ASIA) Impairment Scale. The ASIA Impairment Scale is a standard diagnostic tool that evaluates a patient's motor and sensory function.

[0278] In some embodiments, diagnosing neurotrauma includes measuring an increase in a biomarker associated with neurotrauma in a biological sample from the subject. In some embodiments, the increased biomarker in the biological sample from the subject is at least one selected from aldolase C (ALDOC), brain lipid-binding protein (BLBP / FABP7), trauma-specific degradation products (BDP) of ALDOC or BLBP / FABP7, apolipoprotein B (APOB), prostaglandin synthase (PTGDS), glutamine synthetase (GS), astrocyte phosphoprotein PEA-15 (PEA15), alpha B-crystallin (CRYAB / HSP27), ubiquitin C-terminal hydrolase (UCH-L1), glial fibrillary acidic protein (GFAP), pNF-H, LPA, LPA metabolites, SBDP150, SBDP150i, SBDP145, SBDP120, MAP2, NLRP1 (NALP-1), ASC, caspase-1, and 12-HETE.

[0279] As used herein, a "biological sample" refers to any bodily fluid or tissue obtained from a patient or subject. Biological samples include, but are not limited to, whole blood, red blood cells, plasma, serum, peripheral blood mononuclear cells (PBMCs), urine, saliva, tears, buccal swabs, cerebrospinal fluid (CSF), CNS microdialysate, and neural tissue. In some embodiments, the biological sample is CSF, saliva, serum, plasma, or urine. In certain embodiments, the biological sample is CSF.

[0280] In some embodiments, the disclosure provides methods and compositions for preventing, inhibiting, or delaying the onset of NT by administration to a subject prior to the onset of NT, e.g., prior to the onset of one or more symptoms of NT.

[0281] In some embodiments, the provided method prevents NT. The method can be administered to patients who are at risk of developing NT. In such subjects, the prevention of NT can be monitored by the absence of typical characteristics of NT. For example, the subject who is prophylactically administered an effective amount of HIF1-α inhibitor and an effective amount of PFKFB3 inhibitor may not experience or experience a reduced incidence of one or more of the following symptoms: impaired physical ability, impaired limb motor ability, impaired ability to coordinate muscle groups, impaired sensory function, impaired cognitive ability, headache and / or dizziness.

[0282] In some embodiments, the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are administered after the onset of one or more symptoms of NT. In some embodiments, the methods provided reduce damage to nerve cells or nerve tissue, reduce inflammation of nerve cells or nerve tissue, reduce neurodegeneration or death of nerve cells or nerve tissue, improve function of nerve cells or nerve tissue, improve functional recovery of nerve cells or nerve tissue, such as improving locomotor activity. In some embodiments, the methods provided improve the cognitive status of the subject, as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, treating NT according to the methods provided herein includes delaying the onset of one or more symptoms of NT.

[0283] In some embodiments, the HIF1-α pathway inhibitor administered in accordance with the methods provided herein is an antibody or antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α pathway binding polypeptide, or a small molecule HIF1-α pathway inhibitor.

[0284] In some embodiments, the HIF1-α pathway inhibitor administered is silibinin, PX-478 or YC-1, or a salt thereof.

[0285] In some embodiments, the administered HIF1-α pathway inhibitor is ganetespib (ST-9090), phenethyl isothiocyanate, or BAY-87-2243, or a salt thereof.

[0286] In some embodiments, the HIF1-α pathway inhibitor administered according to the methods provided herein is a HIF1-α inhibitor. In some embodiments, the HIF1-α inhibitor does not inhibit the PI3K / AKT / mTOR pathway. In some embodiments, the HIF1-α inhibitor is an antibody or an antigen-binding fragment thereof (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another engineered molecule, e.g., a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, a MiRNA, a dsRNA, a ssRNA, and a shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, or a small molecule HIF1-α inhibitor.

[0287] In some embodiments, the HIF1-α inhibitor administered is the antisense oligonucleotide EZN-2968, or nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212 or AHPC.

[0288] In some embodiments, the PFKFB3 inhibitor administered according to the methods provided herein is an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, a F(ab')2 fragment, an Fd fragment, an Fv fragment, a scFv, a dAb fragment, or another engineered molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

[0289] In some embodiments, the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), or a salt thereof.

[0290] In some embodiments, the PFKFB3 inhibitor administered is KAN0436151 or KAN0436067, or a salt thereof.

[0291] In some embodiments, the PFKFB3 inhibitor administered is AZ67, or a salt thereof.

[0292] In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula 1-53 or Formula 54, PQP, N4A, YN1, PK15, PFK-158, YZ29, Compound 26, KAN0436151, KAN0436067, or BrAcNHErOP, or a salt thereof, as shown in Figure 1A-1C or Figure 1D. In some embodiments, the administered PFKFB3 inhibitor has the structure of Formula AZ44-AZ70 or AZ71, or a salt thereof, as shown in Figure 1E.

[0293] In some embodiments, the methods provided herein for treating NT are carried out by co-administering to a subject a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0294] In some embodiments, treating NT according to the methods provided herein includes reducing one or more symptoms of NT in a subject, compared to the subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the reduction in one or more symptoms of NT is selected from impaired physical ability, impaired limb movement ability, impaired ability to coordinate muscle groups, impaired sensory function, impaired cognitive ability, headaches, and / or dizziness. In some embodiments, treating NT according to the methods provided herein is indicated by an improvement in mental cognitive status, for example, as measured using a mental cognitive status test (e.g., the Mini-Mental State Examination (MMSE) or the Mini-Cog test). In some embodiments, the improvement in mental cognitive status is indicated by an improvement in the mental cognitive status test score of at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, compared to the subject's cognitive score in the corresponding test before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0295] In some embodiments, treating NT according to the methods provided herein includes alleviating one or more symptoms of NT in a subject, compared to a control or compared to a subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor. In some embodiments, the one or more alleviated symptoms of NT are selected from: reduced apoptosis / destruction / loss of number and / or function of neuronal cells and / or tissues; increased survival and / or function of neuronal cells and / or tissues; reduced long-term damage to neuronal cells / tissues and / or surrounding cells / tissues; reduced inflammation of neuronal cells / tissues; reduced oxidative stress of neuronal cells / tissues; and increased survival / survival. In some embodiments, one or more symptoms of neurotrauma are alleviated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% compared to a control subject or compared to a subject before treatment with a HIF1-α pathway inhibitor and a PFKFB3 inhibitor.

[0296] In some embodiments, the provided method results in a reduction in apoptosis and / or cell death of neural cells or tissue in a subject. Cell death can be monitored according to known methods. Exemplary methods for detecting cell death include, but are not limited to, nuclear staining techniques such as propidium iodide, Hoechst-33342, 4',6-diamidino-2-phenylindole (DAPI), and acridine orange-ethidium bromide staining. Non-nuclear staining techniques include, but are not limited to, Annexin V staining.

[0297] Also provided are methods of reducing the size of cerebral infarcts in subjects known or suspected of having sustained neurotrauma, as well as methods of enhancing locomotor recovery in such subjects.

[0298] In some embodiments, the present disclosure provides methods of treating a subject suffering from or at risk of suffering from a disease characterized by neuronal cell death and suboptimal neuronal survival, including those that occur following neurotrauma, traumatic brain injury, spinal cord injury, or other mechanical events that cause damage to the brain, such as surgical procedures, e.g., brain tumor surgery.

[0299] Treatment of NT can be measured by a variety of means using techniques known in the art. In some embodiments, treatment includes reducing one or more of the following symptoms of NT in a subject: impaired physical ability, impaired ability to move limbs, impaired ability to coordinate muscle groups, impaired sensory function, impaired cognitive ability, headaches, and / or dizziness.

[0300] In additional embodiments, the methods provided include further administering an additional therapeutic agent to the subject.

[0301] The disclosures of each of U.S. patent applications Ser. Nos. 63 / 189,204, 63 / 189,205, 63 / 189,206 and 63 / 189,207, each filed on May 16, 2021, are hereby incorporated by reference in their entireties.

[0302] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entirety for all purposes. However, mention of any references, articles, publications, patents, patent publications, and patent applications cited herein is not, and should not be construed as, an admission or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

Claims

1. 1. A composition for use in treating a neurological disorder in a subject in need thereof, said use comprising: (a) administering to the subject a composition comprising an effective amount of a HIF1-α pathway inhibitor and an effective amount of a PFKFB3 inhibitor; (b) administering to the subject a composition comprising an effective amount of a HIF1-α pathway inhibitor, wherein the subject has previously been administered a PFKFB3 inhibitor; or (c) administering to the subject a composition comprising an effective amount of a PFKFB3 inhibitor, wherein the subject has previously been administered a HIF1-α pathway inhibitor; The PFKFB3 inhibitor does not inhibit the PI3K / AKT / mTOR pathway or HIF1-α; Composition for use.

2. The composition for use described in claim 1, wherein the composition is administered as a preventative treatment for the neurological disease.

3. The composition for use according to claim 1, wherein the neurological disease is a neurodegenerative disease, dementia, neuropathy, or neurotrauma.

4. The administered HIF1-α pathway inhibitor is an antibody or an antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, an F(ab') ２ The composition for use of claim 1, which is a polypeptide that is a polypeptide that is a polypeptide of the present invention, the polypeptide of the present invention being a polypeptide of the present invention, the polypeptide of the present invention being a polypeptide of the present invention.

5. The composition for use according to claim 1, wherein the administered HIF1-α pathway inhibitor is silibinin, PX-478, YC-1, ganetespib (ST-9090), phenethyl isothiocyanate, BAY-87-2243, or a salt thereof.

6. The composition for use of claim 1, wherein the administered HIF1-α pathway inhibitor is a HIF1-α inhibitor and is optionally selected from an antibody or antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody (e.g., VHH), a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a scFv, a dAb fragment, or another modified molecule such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a HIF1-α binding polypeptide, and a small molecule HIF1-α inhibitor.

7. The composition for use according to claim 6, wherein the administered HIF1-α inhibitor is antisense oligonucleotide EZN-2968, nanobody AG-1, AG-2, AG-3, AG-4, AG-5, VHH212, or AHPC. [0010] The administered PFKFB3 inhibitor is an antibody or an antigen-binding antibody fragment (e.g., a single chain antibody, a single domain antibody, a Fab fragment, an F(ab') ２ The composition for use of claim 1, which is a PFKFB3 binding polypeptide, a PFKFB3 fragment, an Fd fragment, an Fv fragment, an scFv, a dAb fragment, or another engineered molecule, such as a diabody, a triabody, a tetrabody, a minibody, and a minimal recognition unit), a nucleic acid molecule (e.g., an aptamer, an antisense molecule, a ribozyme, MiRNA, dsRNA, ssRNA, and shRNA), a peptibody, a nanobody, a PFKFB3 binding polypeptide, or a small molecule PFKFB3 inhibitor.

9. The composition for use according to claim 1, wherein the administered PFKFB3 inhibitor is BrAcNHEtOP (N-bromoacetylethanolamine phosphate), PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), or PFK-158 ((E)-1-(4-pyridinyl)-3-[7-(trifluoromethyl)-2-quinolinyl]-2-propen-1-one), KAN0436151, KAN0436067, or a salt thereof.

10. The composition for use of claim 1, wherein the HIF1-α pathway inhibitor and the PFKFB3 inhibitor are co-administered to the subject, optionally prior to or after the onset of one or more symptoms of the neurological disease, and optionally wherein administration is oral, parenteral, orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intranasal, intratumoral, or intravenous.

11. The composition for use described in claim 1, wherein the use further comprises administering an additional therapeutic agent to the subject, optionally wherein the additional therapeutic agent is selected from an acetylcholinesterase inhibitor, an NMDA receptor antagonist, memantine, a dopamine agonist, levodopa, and tetrabenazine.

12. 2. The composition for use of claim 1, wherein the neurodegenerative disease is selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, frontotemporal lobar degeneration, and dementia with Lewy bodies.

13. The composition for use according to claim 1 , wherein the neurotrauma is a spinal cord injury or a traumatic brain injury.

Images